Search

Your search keyword '"Van Amelsvoort, T."' showing total 534 results
Start Over Author "Van Amelsvoort, T."
534 results on '"Van Amelsvoort, T."'

3. Demographic, clinical, and service-use characteristics related to the clinician’s recommendation to transition from child to adult mental health services

Author

Gerritsen, S. E., van Bodegom, L. S., Dieleman, G. C., Overbeek, M. M., Verhulst, F. C., Wolke, D., Rizopoulos, D., Appleton, R., van Amelsvoort, T. A. M. J., Bodier Rethore, C., Bonnet-Brilhault, F., Charvin, I., Da Fonseca, D., Davidović, N., Dodig-Ćurković, K., Ferrari, A., Fiori, F., Franić, T., Gatherer, C., de Girolamo, G., Heaney, N., Hendrickx, G., Jardri, R., Kolozsvari, A., Lida-Pulik, H., Lievesley, K., Madan, J., Mastroianni, M., Maurice, V., McNicholas, F., Nacinovich, R., Parenti, A., Paul, M., Purper-Ouakil, D., Rivolta, L., de Roeck, V., Russet, F., Saam, M. C., Sagar-Ouriaghli, I., Santosh, P. J., Sartor, A., Schulze, U. M. E., Scocco, P., Signorini, G., Singh, S. P., Singh, J., Speranza, M., Stagi, P., Stagni, P., Street, C., Tah, P., Tanase, E., Tremmery, S., Tuffrey, A., Tuomainen, H., Walker, L., Wilson, A., and Maras, A.

Published
2022
Full Text
View/download PDF

4. Brain charts for the human lifespan

Author

Bethlehem, R. A. I., Seidlitz, J., White, S. R., Vogel, J. W., Anderson, K. M., Adamson, C., Adler, S., Alexopoulos, G. S., Anagnostou, E., Areces-Gonzalez, A., Astle, D. E., Auyeung, B., Ayub, M., Bae, J., Ball, G., Baron-Cohen, S., Beare, R., Bedford, S. A., Benegal, V., Beyer, F., Blangero, J., Blesa Cábez, M., Boardman, J. P., Borzage, M., Bosch-Bayard, J. F., Bourke, N., Calhoun, V. D., Chakravarty, M. M., Chen, C., Chertavian, C., Chetelat, G., Chong, Y. S., Cole, J. H., Corvin, A., Costantino, M., Courchesne, E., Crivello, F., Cropley, V. L., Crosbie, J., Crossley, N., Delarue, M., Delorme, R., Desrivieres, S., Devenyi, G. A., Di Biase, M. A., Dolan, R., Donald, K. A., Donohoe, G., Dunlop, K., Edwards, A. D., Elison, J. T., Ellis, C. T., Elman, J. A., Eyler, L., Fair, D. A., Feczko, E., Fletcher, P. C., Fonagy, P., Franz, C. E., Galan-Garcia, L., Gholipour, A., Giedd, J., Gilmore, J. H., Glahn, D. C., Goodyer, I. M., Grant, P. E., Groenewold, N. A., Gunning, F. M., Gur, R. E., Gur, R. C., Hammill, C. F., Hansson, O., Hedden, T., Heinz, A., Henson, R. N., Heuer, K., Hoare, J., Holla, B., Holmes, A. J., Holt, R., Huang, H., Im, K., Ipser, J., Jack, Jr, C. R., Jackowski, A. P., Jia, T., Johnson, K. A., Jones, P. B., Jones, D. T., Kahn, R. S., Karlsson, H., Karlsson, L., Kawashima, R., Kelley, E. A., Kern, S., Kim, K. W., Kitzbichler, M. G., Kremen, W. S., Lalonde, F., Landeau, B., Lee, S., Lerch, J., Lewis, J. D., Li, J., Liao, W., Liston, C., Lombardo, M. V., Lv, J., Lynch, C., Mallard, T. T., Marcelis, M., Markello, R. D., Mathias, S. R., Mazoyer, B., McGuire, P., Meaney, M. J., Mechelli, A., Medic, N., Misic, B., Morgan, S. E., Mothersill, D., Nigg, J., Ong, M. Q. W., Ortinau, C., Ossenkoppele, R., Ouyang, M., Palaniyappan, L., Paly, L., Pan, P. M., Pantelis, C., Park, M. M., Paus, T., Pausova, Z., Paz-Linares, D., Pichet Binette, A., Pierce, K., Qian, X., Qiu, J., Qiu, A., Raznahan, A., Rittman, T., Rodrigue, A., Rollins, C. K., Romero-Garcia, R., Ronan, L., Rosenberg, M. D., Rowitch, D. H., Salum, G. A., Satterthwaite, T. D., Schaare, H. L., Schachar, R. J., Schultz, A. P., Schumann, G., Schöll, M., Sharp, D., Shinohara, R. T., Skoog, I., Smyser, C. D., Sperling, R. A., Stein, D. J., Stolicyn, A., Suckling, J., Sullivan, G., Taki, Y., Thyreau, B., Toro, R., Traut, N., Tsvetanov, K. A., Turk-Browne, N. B., Tuulari, J. J., Tzourio, C., Vachon-Presseau, É., Valdes-Sosa, M. J., Valdes-Sosa, P. A., Valk, S. L., van Amelsvoort, T., Vandekar, S. N., Vasung, L., Victoria, L. W., Villeneuve, S., Villringer, A., Vértes, P. E., Wagstyl, K., Wang, Y. S., Warfield, S. K., Warrier, V., Westman, E., Westwater, M. L., Whalley, H. C., Witte, A. V., Yang, N., Yeo, B., Yun, H., Zalesky, A., Zar, H. J., Zettergren, A., Zhou, J. H., Ziauddeen, H., Zugman, A., Zuo, X. N., Bullmore, E. T., and Alexander-Bloch, A. F.

Published
2022
Full Text
View/download PDF

6. Publisher Correction: Brain charts for the human lifespan

Author

Bethlehem, R. A. I., Seidlitz, J., White, S. R., Vogel, J. W., Anderson, K. M., Adamson, C., Adler, S., Alexopoulos, G. S., Anagnostou, E., Areces-Gonzalez, A., Astle, D. E., Auyeung, B., Ayub, M., Bae, J., Ball, G., Baron-Cohen, S., Beare, R., Bedford, S. A., Benegal, V., Beyer, F., Blangero, J., Blesa Cábez, M., Boardman, J. P., Borzage, M., Bosch-Bayard, J. F., Bourke, N., Calhoun, V. D., Chakravarty, M. M., Chen, C., Chertavian, C., Chetelat, G., Chong, Y. S., Cole, J. H., Corvin, A., Costantino, M., Courchesne, E., Crivello, F., Cropley, V. L., Crosbie, J., Crossley, N., Delarue, M., Delorme, R., Desrivieres, S., Devenyi, G. A., Di Biase, M. A., Dolan, R., Donald, K. A., Donohoe, G., Dunlop, K., Edwards, A. D., Elison, J. T., Ellis, C. T., Elman, J. A., Eyler, L., Fair, D. A., Feczko, E., Fletcher, P. C., Fonagy, P., Franz, C. E., Galan-Garcia, L., Gholipour, A., Giedd, J., Gilmore, J. H., Glahn, D. C., Goodyer, I. M., Grant, P. E., Groenewold, N. A., Gunning, F. M., Gur, R. E., Gur, R. C., Hammill, C. F., Hansson, O., Hedden, T., Heinz, A., Henson, R. N., Heuer, K., Hoare, J., Holla, B., Holmes, A. J., Holt, R., Huang, H., Im, K., Ipser, J., Jack, Jr, C. R., Jackowski, A. P., Jia, T., Johnson, K. A., Jones, P. B., Jones, D. T., Kahn, R. S., Karlsson, H., Karlsson, L., Kawashima, R., Kelley, E. A., Kern, S., Kim, K. W., Kitzbichler, M. G., Kremen, W. S., Lalonde, F., Landeau, B., Lee, S., Lerch, J., Lewis, J. D., Li, J., Liao, W., Liston, C., Lombardo, M. V., Lv, J., Lynch, C., Mallard, T. T., Marcelis, M., Markello, R. D., Mathias, S. R., Mazoyer, B., McGuire, P., Meaney, M. J., Mechelli, A., Medic, N., Misic, B., Morgan, S. E., Mothersill, D., Nigg, J., Ong, M. Q. W., Ortinau, C., Ossenkoppele, R., Ouyang, M., Palaniyappan, L., Paly, L., Pan, P. M., Pantelis, C., Park, M. M., Paus, T., Pausova, Z., Paz-Linares, D., Pichet Binette, A., Pierce, K., Qian, X., Qiu, J., Qiu, A., Raznahan, A., Rittman, T., Rodrigue, A., Rollins, C. K., Romero-Garcia, R., Ronan, L., Rosenberg, M. D., Rowitch, D. H., Salum, G. A., Satterthwaite, T. D., Schaare, H. L., Schachar, R. J., Schultz, A. P., Schumann, G., Schöll, M., Sharp, D., Shinohara, R. T., Skoog, I., Smyser, C. D., Sperling, R. A., Stein, D. J., Stolicyn, A., Suckling, J., Sullivan, G., Taki, Y., Thyreau, B., Toro, R., Traut, N., Tsvetanov, K. A., Turk-Browne, N. B., Tuulari, J. J., Tzourio, C., Vachon-Presseau, É., Valdes-Sosa, M. J., Valdes-Sosa, P. A., Valk, S. L., van Amelsvoort, T., Vandekar, S. N., Vasung, L., Victoria, L. W., Villeneuve, S., Villringer, A., Vértes, P. E., Wagstyl, K., Wang, Y. S., Warfield, S. K., Warrier, V., Westman, E., Westwater, M. L., Whalley, H. C., Witte, A. V., Yang, N., Yeo, B., Yun, H., Zalesky, A., Zar, H. J., Zettergren, A., Zhou, J. H., Ziauddeen, H., Zugman, A., Zuo, X. N., Bullmore, E. T., and Alexander-Bloch, A. F.

Published
2022
Full Text
View/download PDF

7. Demographic, clinical, and service-use characteristics related to the clinician’s recommendation to transition from child to adult mental health services

Author

Gerritsen, S, van Bodegom, L, Dieleman, G, Overbeek, M, Verhulst, F, Wolke, D, Rizopoulos, D, Appleton, R, van Amelsvoort, T, Bodier Rethore, C, Bonnet-Brilhault, F, Charvin, I, Da Fonseca, D, Davidovic, N, Dodig-Curkovic, K, Ferrari, A, Fiori, F, Franic, T, Gatherer, C, de Girolamo, G, Heaney, N, Hendrickx, G, Jardri, R, Kolozsvari, A, Lida-Pulik, H, Lievesley, K, Madan, J, Mastroianni, M, Maurice, V, Mcnicholas, F, Nacinovich, R, Parenti, A, Paul, M, Purper-Ouakil, D, Rivolta, L, de Roeck, V, Russet, F, Saam, M, Sagar-Ouriaghli, I, Santosh, P, Sartor, A, Schulze, U, Scocco, P, Signorini, G, Singh, S, Singh, J, Speranza, M, Stagi, P, Stagni, P, Street, C, Tah, P, Tanase, E, Tremmery, S, Tuffrey, A, Tuomainen, H, Walker, L, Wilson, A, Maras, A, Adams, L, Allibrio, G, Armando, M, Aslan, S, Baccanelli, N, Balaudo, M, Bergamo, F, Bertani, A, Berriman, J, Boon, A, Braamse, K, Breuninger, U, Buttiglione, M, Buttle, S, Schandrin, A, Cammarano, M, Canaway, A, Cantini, F, Cappellari, C, Carenini, M, Carra, G, Ferrari, C, Chianura, K, Coleman, P, Colonna, A, Conese, P, Costanzo, R, Daffern, C, Danckaerts, M, de Giacomo, A, Ermans, J, Farmer, A, Fegert, J, Ferrari, S, Galea, G, Gatta, M, Gheza, E, Goglia, G, Grandetto, M, Griffin, J, Levi, F, Humbertclaude, V, Ingravallo, N, Invernizzi, R, Kelly, C, Killilea, M, Kirwan, J, Klockaerts, C, Kovac, V, Liew, A, Lippens, C, Macchi, F, Manenti, L, Margari, F, Margari, L, Martinelli, P, Mcfadden, L, Menghini, D, Miller, S, Monzani, E, Morini, G, Mutafov, T, O'Hara, L, Negrinotti, C, Nelis, E, Neri, F, Nikolova, P, Nossa, M, Cataldo, M, Noterdaeme, M, Operto, F, Panaro, V, Pastore, A, Pemmaraju, V, Pepermans, A, Petruzzelli, M, Presicci, A, Prigent, C, Rinaldi, F, Riva, E, Roekens, A, Rogers, B, Ronzini, P, Sakar, V, Salvetti, S, Martinelli, O, Sandhu, T, Schepker, R, Siviero, M, Slowik, M, Smyth, C, Conti, P, Spadone, M, Starace, F, Stoppa, P, Tansini, L, Toselli, C, Trabucchi, G, Tubito, M, van Dam, A, van Gutschoven, H, van West, D, Vanni, F, Vannicola, C, Varuzza, C, Varvara, P, Ventura, P, Vicari, S, Vicini, S, von Bentzel, C, Wells, P, Williams, B, Zabarella, M, Zamboni, A, Zanetti, E, Gerritsen S. E., van Bodegom L. S., Dieleman G. C., Overbeek M. M., Verhulst F. C., Wolke D., Rizopoulos D., Appleton R., van Amelsvoort T. A. M. J., Bodier Rethore C., Bonnet-Brilhault F., Charvin I., Da Fonseca D., Davidovic N., Dodig-Curkovic K., Ferrari A., Fiori F., Franic T., Gatherer C., de Girolamo G., Heaney N., Hendrickx G., Jardri R., Kolozsvari A., Lida-Pulik H., Lievesley K., Madan J., Mastroianni M., Maurice V., McNicholas F., Nacinovich R., Parenti A., Paul M., Purper-Ouakil D., Rivolta L., de Roeck V., Russet F., Saam M. C., Sagar-Ouriaghli I., Santosh P. J., Sartor A., Schulze U. M. E., Scocco P., Signorini G., Singh S. P., Singh J., Speranza M., Stagi P., Stagni P., Street C., Tah P., Tanase E., Tremmery S., Tuffrey A., Tuomainen H., Walker L., Wilson A., Maras A., Adams L., Allibrio G., Armando M., Aslan S., Baccanelli N., Balaudo M., Bergamo F., Bertani A., Berriman J., Boon A., Braamse K., Breuninger U., Buttiglione M., Buttle S., Schandrin A., Cammarano M., Canaway A., Cantini F., Cappellari C., Carenini M., Carra G., Ferrari C., Chianura K., Coleman P., Colonna A., Conese P., Costanzo R., Daffern C., Danckaerts M., de Giacomo A., Ermans J. -P., Farmer A., Fegert J. M., Ferrari S., Galea G., Gatta M., Gheza E., Goglia G., Grandetto M. R., Griffin J., Levi F. M., Humbertclaude V., Ingravallo N., Invernizzi R., Kelly C., Killilea M., Kirwan J., Klockaerts C., Kovac V., Liew A., Lippens C., Macchi F., Manenti L., Margari F., Margari L., Martinelli P., McFadden L., Menghini D., Miller S., Monzani E., Morini G., Mutafov T., O'Hara L., Negrinotti C., Nelis E., Neri F., Nikolova P., Nossa M., Cataldo M. G., Noterdaeme M., Operto F., Panaro V., Pastore A., Pemmaraju V., Pepermans A., Petruzzelli M. G., Presicci A., Prigent C., Rinaldi F., Riva E., Roekens A., Rogers B., Ronzini P., Sakar V., Salvetti S., Martinelli O., Sandhu T., Schepker R., Siviero M., Slowik M., Smyth C., Conti P., Spadone M. A., Starace F., Stoppa P., Tansini L., Toselli C., Trabucchi G., Tubito M., van Dam A., van Gutschoven H., van West D., Vanni F., Vannicola C., Varuzza C., Varvara P., Ventura P., Vicari S., Vicini S., von Bentzel C., Wells P., Williams B., Zabarella M., Zamboni A., Zanetti E., Gerritsen, S, van Bodegom, L, Dieleman, G, Overbeek, M, Verhulst, F, Wolke, D, Rizopoulos, D, Appleton, R, van Amelsvoort, T, Bodier Rethore, C, Bonnet-Brilhault, F, Charvin, I, Da Fonseca, D, Davidovic, N, Dodig-Curkovic, K, Ferrari, A, Fiori, F, Franic, T, Gatherer, C, de Girolamo, G, Heaney, N, Hendrickx, G, Jardri, R, Kolozsvari, A, Lida-Pulik, H, Lievesley, K, Madan, J, Mastroianni, M, Maurice, V, Mcnicholas, F, Nacinovich, R, Parenti, A, Paul, M, Purper-Ouakil, D, Rivolta, L, de Roeck, V, Russet, F, Saam, M, Sagar-Ouriaghli, I, Santosh, P, Sartor, A, Schulze, U, Scocco, P, Signorini, G, Singh, S, Singh, J, Speranza, M, Stagi, P, Stagni, P, Street, C, Tah, P, Tanase, E, Tremmery, S, Tuffrey, A, Tuomainen, H, Walker, L, Wilson, A, Maras, A, Adams, L, Allibrio, G, Armando, M, Aslan, S, Baccanelli, N, Balaudo, M, Bergamo, F, Bertani, A, Berriman, J, Boon, A, Braamse, K, Breuninger, U, Buttiglione, M, Buttle, S, Schandrin, A, Cammarano, M, Canaway, A, Cantini, F, Cappellari, C, Carenini, M, Carra, G, Ferrari, C, Chianura, K, Coleman, P, Colonna, A, Conese, P, Costanzo, R, Daffern, C, Danckaerts, M, de Giacomo, A, Ermans, J, Farmer, A, Fegert, J, Ferrari, S, Galea, G, Gatta, M, Gheza, E, Goglia, G, Grandetto, M, Griffin, J, Levi, F, Humbertclaude, V, Ingravallo, N, Invernizzi, R, Kelly, C, Killilea, M, Kirwan, J, Klockaerts, C, Kovac, V, Liew, A, Lippens, C, Macchi, F, Manenti, L, Margari, F, Margari, L, Martinelli, P, Mcfadden, L, Menghini, D, Miller, S, Monzani, E, Morini, G, Mutafov, T, O'Hara, L, Negrinotti, C, Nelis, E, Neri, F, Nikolova, P, Nossa, M, Cataldo, M, Noterdaeme, M, Operto, F, Panaro, V, Pastore, A, Pemmaraju, V, Pepermans, A, Petruzzelli, M, Presicci, A, Prigent, C, Rinaldi, F, Riva, E, Roekens, A, Rogers, B, Ronzini, P, Sakar, V, Salvetti, S, Martinelli, O, Sandhu, T, Schepker, R, Siviero, M, Slowik, M, Smyth, C, Conti, P, Spadone, M, Starace, F, Stoppa, P, Tansini, L, Toselli, C, Trabucchi, G, Tubito, M, van Dam, A, van Gutschoven, H, van West, D, Vanni, F, Vannicola, C, Varuzza, C, Varvara, P, Ventura, P, Vicari, S, Vicini, S, von Bentzel, C, Wells, P, Williams, B, Zabarella, M, Zamboni, A, Zanetti, E, Gerritsen S. E., van Bodegom L. S., Dieleman G. C., Overbeek M. M., Verhulst F. C., Wolke D., Rizopoulos D., Appleton R., van Amelsvoort T. A. M. J., Bodier Rethore C., Bonnet-Brilhault F., Charvin I., Da Fonseca D., Davidovic N., Dodig-Curkovic K., Ferrari A., Fiori F., Franic T., Gatherer C., de Girolamo G., Heaney N., Hendrickx G., Jardri R., Kolozsvari A., Lida-Pulik H., Lievesley K., Madan J., Mastroianni M., Maurice V., McNicholas F., Nacinovich R., Parenti A., Paul M., Purper-Ouakil D., Rivolta L., de Roeck V., Russet F., Saam M. C., Sagar-Ouriaghli I., Santosh P. J., Sartor A., Schulze U. M. E., Scocco P., Signorini G., Singh S. P., Singh J., Speranza M., Stagi P., Stagni P., Street C., Tah P., Tanase E., Tremmery S., Tuffrey A., Tuomainen H., Walker L., Wilson A., Maras A., Adams L., Allibrio G., Armando M., Aslan S., Baccanelli N., Balaudo M., Bergamo F., Bertani A., Berriman J., Boon A., Braamse K., Breuninger U., Buttiglione M., Buttle S., Schandrin A., Cammarano M., Canaway A., Cantini F., Cappellari C., Carenini M., Carra G., Ferrari C., Chianura K., Coleman P., Colonna A., Conese P., Costanzo R., Daffern C., Danckaerts M., de Giacomo A., Ermans J. -P., Farmer A., Fegert J. M., Ferrari S., Galea G., Gatta M., Gheza E., Goglia G., Grandetto M. R., Griffin J., Levi F. M., Humbertclaude V., Ingravallo N., Invernizzi R., Kelly C., Killilea M., Kirwan J., Klockaerts C., Kovac V., Liew A., Lippens C., Macchi F., Manenti L., Margari F., Margari L., Martinelli P., McFadden L., Menghini D., Miller S., Monzani E., Morini G., Mutafov T., O'Hara L., Negrinotti C., Nelis E., Neri F., Nikolova P., Nossa M., Cataldo M. G., Noterdaeme M., Operto F., Panaro V., Pastore A., Pemmaraju V., Pepermans A., Petruzzelli M. G., Presicci A., Prigent C., Rinaldi F., Riva E., Roekens A., Rogers B., Ronzini P., Sakar V., Salvetti S., Martinelli O., Sandhu T., Schepker R., Siviero M., Slowik M., Smyth C., Conti P., Spadone M. A., Starace F., Stoppa P., Tansini L., Toselli C., Trabucchi G., Tubito M., van Dam A., van Gutschoven H., van West D., Vanni F., Vannicola C., Varuzza C., Varvara P., Ventura P., Vicari S., Vicini S., von Bentzel C., Wells P., Williams B., Zabarella M., Zamboni A., and Zanetti E.

Abstract

Purpose: The service configuration with distinct child and adolescent mental health services (CAMHS) and adult mental health services (AMHS) may be a barrier to continuity of care. Because of a lack of transition policy, CAMHS clinicians have to decide whether and when a young person should transition to AMHS. This study describes which characteristics are associated with the clinicians’ advice to continue treatment at AMHS. Methods: Demographic, family, clinical, treatment, and service-use characteristics of the MILESTONE cohort of 763 young people from 39 CAMHS in Europe were assessed using multi-informant and standardized assessment tools. Logistic mixed models were fitted to assess the relationship between these characteristics and clinicians’ transition recommendations. Results: Young people with higher clinician-rated severity of psychopathology scores, with self- and parent-reported need for ongoing treatment, with lower everyday functional skills and without self-reported psychotic experiences were more likely to be recommended to continue treatment. Among those who had been recommended to continue treatment, young people who used psychotropic medication, who had been in CAMHS for more than a year, and for whom appropriate AMHS were available were more likely to be recommended to continue treatment at AMHS. Young people whose parents indicated a need for ongoing treatment were more likely to be recommended to stay in CAMHS. Conclusion: Although the decision regarding continuity of treatment was mostly determined by a small set of clinical characteristics, the recommendation to continue treatment at AMHS was mostly affected by service-use related characteristics, such as the availability of appropriate services.

Published
2022

8. Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

Author

Constantinides, C, Han, LKM, Alloza, C, Antonucci, LA, Arango, C, Ayesa-Arriola, R, Banaj, N, Bertolino, A, Borgwardt, S, Bruggemann, J, Bustillo, J, Bykhovski, O, Calhoun, V, Carr, V, Catts, S, Chung, Y-C, Crespo-Facorro, B, Diaz-Caneja, CM, Donohoe, G, Du Plessis, S, Edmond, J, Ehrlich, S, Emsley, R, Eyler, LT, Fuentes-Claramonte, P, Georgiadis, F, Green, M, Guerrero-Pedraza, A, Ha, M, Hahn, T, Henskens, FA, Holleran, L, Homan, S, Homan, P, Jahanshad, N, Janssen, J, Ji, E, Kaiser, S, Kaleda, V, Kim, M, Kim, W-S, Kirschner, M, Kochunov, P, Kwak, YB, Kwon, JS, Lebedeva, I, Liu, J, Mitchie, P, Michielse, S, Mothersill, D, Mowry, B, de la Foz, VO-G, Pantelis, C, Pergola, G, Piras, F, Pomarol-Clotet, E, Preda, A, Quide, Y, Rasser, PE, Rootes-Murdy, K, Salvador, R, Sangiuliano, M, Sarro, S, Schall, U, Schmidt, A, Scott, RJ, Selvaggi, P, Sim, K, Skoch, A, Spalletta, G, Spaniel, F, Thomopoulos, S, Tomecek, D, Tomyshev, AS, Tordesillas-Gutierrez, D, van Amelsvoort, T, Vazquez-Bourgon, J, Vecchio, D, Voineskos, A, Weickert, CS, Weickert, T, Thompson, PM, Schmaal, L, van Erp, TGM, Turner, J, Cole, JH, Dima, D, Walton, E, Constantinides, C, Han, LKM, Alloza, C, Antonucci, LA, Arango, C, Ayesa-Arriola, R, Banaj, N, Bertolino, A, Borgwardt, S, Bruggemann, J, Bustillo, J, Bykhovski, O, Calhoun, V, Carr, V, Catts, S, Chung, Y-C, Crespo-Facorro, B, Diaz-Caneja, CM, Donohoe, G, Du Plessis, S, Edmond, J, Ehrlich, S, Emsley, R, Eyler, LT, Fuentes-Claramonte, P, Georgiadis, F, Green, M, Guerrero-Pedraza, A, Ha, M, Hahn, T, Henskens, FA, Holleran, L, Homan, S, Homan, P, Jahanshad, N, Janssen, J, Ji, E, Kaiser, S, Kaleda, V, Kim, M, Kim, W-S, Kirschner, M, Kochunov, P, Kwak, YB, Kwon, JS, Lebedeva, I, Liu, J, Mitchie, P, Michielse, S, Mothersill, D, Mowry, B, de la Foz, VO-G, Pantelis, C, Pergola, G, Piras, F, Pomarol-Clotet, E, Preda, A, Quide, Y, Rasser, PE, Rootes-Murdy, K, Salvador, R, Sangiuliano, M, Sarro, S, Schall, U, Schmidt, A, Scott, RJ, Selvaggi, P, Sim, K, Skoch, A, Spalletta, G, Spaniel, F, Thomopoulos, S, Tomecek, D, Tomyshev, AS, Tordesillas-Gutierrez, D, van Amelsvoort, T, Vazquez-Bourgon, J, Vecchio, D, Voineskos, A, Weickert, CS, Weickert, T, Thompson, PM, Schmaal, L, van Erp, TGM, Turner, J, Cole, JH, Dima, D, and Walton, E

Abstract

Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18-72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18-73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen's d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions.

Published
2023

9. Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium.

Author

Schijven, D, Postema, MC, Fukunaga, M, Matsumoto, J, Miura, K, de Zwarte, SMC, van Haren, NEM, Cahn, W, Hulshoff Pol, HE, Kahn, RS, Ayesa-Arriola, R, Ortiz-García de la Foz, V, Tordesillas-Gutierrez, D, Vázquez-Bourgon, J, Crespo-Facorro, B, Alnæs, D, Dahl, A, Westlye, LT, Agartz, I, Andreassen, OA, Jönsson, EG, Kochunov, P, Bruggemann, JM, Catts, SV, Michie, PT, Mowry, BJ, Quidé, Y, Rasser, PE, Schall, U, Scott, RJ, Carr, VJ, Green, MJ, Henskens, FA, Loughland, CM, Pantelis, C, Weickert, CS, Weickert, TW, de Haan, L, Brosch, K, Pfarr, J-K, Ringwald, KG, Stein, F, Jansen, A, Kircher, TTJ, Nenadić, I, Krämer, B, Gruber, O, Satterthwaite, TD, Bustillo, J, Mathalon, DH, Preda, A, Calhoun, VD, Ford, JM, Potkin, SG, Chen, J, Tan, Y, Wang, Z, Xiang, H, Fan, F, Bernardoni, F, Ehrlich, S, Fuentes-Claramonte, P, Garcia-Leon, MA, Guerrero-Pedraza, A, Salvador, R, Sarró, S, Pomarol-Clotet, E, Ciullo, V, Piras, F, Vecchio, D, Banaj, N, Spalletta, G, Michielse, S, van Amelsvoort, T, Dickie, EW, Voineskos, AN, Sim, K, Ciufolini, S, Dazzan, P, Murray, RM, Kim, W-S, Chung, Y-C, Andreou, C, Schmidt, A, Borgwardt, S, McIntosh, AM, Whalley, HC, Lawrie, SM, du Plessis, S, Luckhoff, HK, Scheffler, F, Emsley, R, Grotegerd, D, Lencer, R, Dannlowski, U, Edmond, JT, Rootes-Murdy, K, Stephen, JM, Mayer, AR, Antonucci, LA, Fazio, L, Pergola, G, Bertolino, A, Díaz-Caneja, CM, Janssen, J, Lois, NG, Arango, C, Tomyshev, AS, Lebedeva, I, Cervenka, S, Sellgren, CM, Georgiadis, F, Kirschner, M, Kaiser, S, Hajek, T, Skoch, A, Spaniel, F, Kim, M, Kwak, YB, Oh, S, Kwon, JS, James, A, Bakker, G, Knöchel, C, Stäblein, M, Oertel, V, Uhlmann, A, Howells, FM, Stein, DJ, Temmingh, HS, Diaz-Zuluaga, AM, Pineda-Zapata, JA, López-Jaramillo, C, Homan, S, Ji, E, Surbeck, W, Homan, P, Fisher, SE, Franke, B, Glahn, DC, Gur, RC, Hashimoto, R, Jahanshad, N, Luders, E, Medland, SE, Thompson, PM, Turner, JA, van Erp, TGM, Francks, C, Schijven, D, Postema, MC, Fukunaga, M, Matsumoto, J, Miura, K, de Zwarte, SMC, van Haren, NEM, Cahn, W, Hulshoff Pol, HE, Kahn, RS, Ayesa-Arriola, R, Ortiz-García de la Foz, V, Tordesillas-Gutierrez, D, Vázquez-Bourgon, J, Crespo-Facorro, B, Alnæs, D, Dahl, A, Westlye, LT, Agartz, I, Andreassen, OA, Jönsson, EG, Kochunov, P, Bruggemann, JM, Catts, SV, Michie, PT, Mowry, BJ, Quidé, Y, Rasser, PE, Schall, U, Scott, RJ, Carr, VJ, Green, MJ, Henskens, FA, Loughland, CM, Pantelis, C, Weickert, CS, Weickert, TW, de Haan, L, Brosch, K, Pfarr, J-K, Ringwald, KG, Stein, F, Jansen, A, Kircher, TTJ, Nenadić, I, Krämer, B, Gruber, O, Satterthwaite, TD, Bustillo, J, Mathalon, DH, Preda, A, Calhoun, VD, Ford, JM, Potkin, SG, Chen, J, Tan, Y, Wang, Z, Xiang, H, Fan, F, Bernardoni, F, Ehrlich, S, Fuentes-Claramonte, P, Garcia-Leon, MA, Guerrero-Pedraza, A, Salvador, R, Sarró, S, Pomarol-Clotet, E, Ciullo, V, Piras, F, Vecchio, D, Banaj, N, Spalletta, G, Michielse, S, van Amelsvoort, T, Dickie, EW, Voineskos, AN, Sim, K, Ciufolini, S, Dazzan, P, Murray, RM, Kim, W-S, Chung, Y-C, Andreou, C, Schmidt, A, Borgwardt, S, McIntosh, AM, Whalley, HC, Lawrie, SM, du Plessis, S, Luckhoff, HK, Scheffler, F, Emsley, R, Grotegerd, D, Lencer, R, Dannlowski, U, Edmond, JT, Rootes-Murdy, K, Stephen, JM, Mayer, AR, Antonucci, LA, Fazio, L, Pergola, G, Bertolino, A, Díaz-Caneja, CM, Janssen, J, Lois, NG, Arango, C, Tomyshev, AS, Lebedeva, I, Cervenka, S, Sellgren, CM, Georgiadis, F, Kirschner, M, Kaiser, S, Hajek, T, Skoch, A, Spaniel, F, Kim, M, Kwak, YB, Oh, S, Kwon, JS, James, A, Bakker, G, Knöchel, C, Stäblein, M, Oertel, V, Uhlmann, A, Howells, FM, Stein, DJ, Temmingh, HS, Diaz-Zuluaga, AM, Pineda-Zapata, JA, López-Jaramillo, C, Homan, S, Ji, E, Surbeck, W, Homan, P, Fisher, SE, Franke, B, Glahn, DC, Gur, RC, Hashimoto, R, Jahanshad, N, Luders, E, Medland, SE, Thompson, PM, Turner, JA, van Erp, TGM, and Francks, C

Abstract

Left-right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case-control study of structural brain asymmetries in schizophrenia, with MRI data from 5,080 affected individuals and 6,015 controls across 46 datasets, using a single image analysis protocol. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Small average case-control differences were observed for thickness asymmetries of the rostral anterior cingulate and the middle temporal gyrus, both driven by thinner left-hemispheric cortices in schizophrenia. Analyses of these asymmetries with respect to the use of antipsychotic medication and other clinical variables did not show any significant associations. Assessment of age- and sex-specific effects revealed a stronger average leftward asymmetry of pallidum volume between older cases and controls. Case-control differences in a multivariate context were assessed in a subset of the data (N = 2,029), which revealed that 7% of the variance across all structural asymmetries was explained by case-control status. Subtle case-control differences of brain macrostructural asymmetry may reflect differences at the molecular, cytoarchitectonic, or circuit levels that have functional relevance for the disorder. Reduced left middle temporal cortical thickness is consistent with altered left-hemisphere language network organization in schizophrenia.

Published
2023

10. Psychosis Endophenotypes:A Gene-Set-Specific Polygenic Risk Score Analysis

Author

Wang, BH, Irizar, H, Thygesen, JH, Zartaloudi, E, Austin-Zimmerman, I, Bhat, A, Harju-Seppaenen, J, Pain, O, Bass, N, Gkofa, V, Alizadeh, BZ, van Amelsvoort, T, Arranz, MJ, Bender, S, Cahn, W, Calafato, MS, Crespo-Facorro, B, Di Forti, M, Giegling, I, de Haan, L, Hall, J, Hall, MH, van Haren, N, Iyegbe, C, Kahn, RS, Kravariti, E, Lawrie, SM, Lin, K, Luykx, JJ, Mata, I, McDonald, C, McIntosh, AM, Murray, RM, Picchioni, M, Powell, J, Prata, DP, Rujescu, D, Rutten, BPF, Shaikh, M, Simons, CJP, Toulopoulou, T, Weisbrod, M, van Winkel, R, Kuchenbaecker, K, McQuillin, A, Bramon, E, Wang, BH, Irizar, H, Thygesen, JH, Zartaloudi, E, Austin-Zimmerman, I, Bhat, A, Harju-Seppaenen, J, Pain, O, Bass, N, Gkofa, V, Alizadeh, BZ, van Amelsvoort, T, Arranz, MJ, Bender, S, Cahn, W, Calafato, MS, Crespo-Facorro, B, Di Forti, M, Giegling, I, de Haan, L, Hall, J, Hall, MH, van Haren, N, Iyegbe, C, Kahn, RS, Kravariti, E, Lawrie, SM, Lin, K, Luykx, JJ, Mata, I, McDonald, C, McIntosh, AM, Murray, RM, Picchioni, M, Powell, J, Prata, DP, Rujescu, D, Rutten, BPF, Shaikh, M, Simons, CJP, Toulopoulou, T, Weisbrod, M, van Winkel, R, Kuchenbaecker, K, McQuillin, A, and Bramon, E

Abstract

Background and Hypothesis: Endophenotypes can help to bridge the gap between psychosis and its genetic predispositions, but their underlying mechanisms remain largely unknown. This study aims to identify biological mechanisms that are relevant to the endophenotypes for psychosis, by partitioning polygenic risk scores into specific gene sets and testing their associations with endophenotypes. Study Design: We computed polygenic risk scores for schizophrenia and bipolar disorder restricted to brain-related gene sets retrieved from public databases and previous publications. Three hundred and seventy-eight gene-set-specific polygenic risk scores were generated for 4506 participants. Seven endophenotypes were also measured in the sample. Linear mixed-effects models were fitted to test associations between each endophenotype and each gene-set-specific polygenic risk score. Study Results: After correction for multiple testing, we found that a reduced P300 amplitude was associated with a higher schizophrenia polygenic risk score of the forebrain regionalization gene set (mean difference per SD increase in the polygenic risk score: −1.15 µV; 95% CI: −1.70 to −0.59 µV; P = 6 × 10−5). The schizophrenia polygenic risk score of forebrain regionalization also explained more variance of the P300 amplitude (R2 = 0.032) than other polygenic risk scores, including the genome-wide polygenic risk scores. Conclusions: Our finding on reduced P300 amplitudes suggests that certain genetic variants alter early brain development thereby increasing schizophrenia risk years later. Gene-set-specific polygenic risk scores are a useful tool to elucidate biological mechanisms of psychosis and endophenotypes, offering leads for experimental validation in cellular and animal models.

Published
2023

11. Delayed affective recovery to daily-life stressors signals a risk for depression

Author

De Calheiros Velozo, J, Lafit, G, Viechtbauer, W, van Amelsvoort, T, Schruers, K, Marcelis, M, Goossens, L, Simons, C J P, Delespaul, P, Claes, S, Myin-Germeys, I, Vaessen, T, De Calheiros Velozo, J, Lafit, G, Viechtbauer, W, van Amelsvoort, T, Schruers, K, Marcelis, M, Goossens, L, Simons, C J P, Delespaul, P, Claes, S, Myin-Germeys, I, and Vaessen, T

Abstract

OBJECTIVE: The aim of this study is to investigate the time to affective recovery from daily-life stressors between healthy controls (HC) and two groups with an increased risk for developing depression: individuals with subclinical symptoms of depression (SSD), and individuals remitted from a depressive episode with residual symptoms of depression (RRS).METHOD: The experience sampling method (ESM) was used to measure affective recovery to daily-life stressors. Affective recovery was defined as the moment that negative affect (NA) returned to baseline level following the first stressful event of the day. We assessed two different operationalizations of the baseline: NA at the moment before the stressful event (t-1), and mean-person NA. The effect of stress intensity, and cumulative stress were also assessed.RESULTS: Survival analyses showed significantly longer recovery times for the at risk groups in comparison to healthy individuals, albeit no significant difference was found between the two at risk groups (i.e. SSD and RRS). There was also an effect of cumulative stress, but not stress intensity on time to recovery in that cumulative stress resulted in significantly longer recovery times for all three groups.LIMITATIONS: The present study is limited by the ESM sampling design, assessments take place post-stress and therefore do not capture peak stress. Additionally, we are only able to assess patterns at the group level. Finally, there is a significant age difference between groups.CONCLUSION: Individuals at risk for depression display a delayed recovery to daily-life stressors when compared to healthy controls, which is not explained by differences in stress intensity or cumulative stress. Understanding what is driving this delay may help combat the development of depression.

Published
2023

12. Associations between polygenic risk score loading, psychosis liability, and clozapine use among individuals with schizophrenia

Author

Lin, B.D., Pinzón-Espinosa, J., Blouzard, E., Van Der Horst, M.Z., Okhuijsen-pfeifer, C., Van Eijk, K.R., Guloksuz, S., Peyrot, W.J., Luykx, J.J., Hasan, A., Wagner, E., Pantelis, C., Everall, I.P., Ayhan, Y., Babaoğlu, M.O., Bak, M., Alink, W., Beld, E, Bouhuis, A., Edlinger, M., Erdoğan, I.M., Gutwinski, S., Hallikainen, T., Jeger-land, E., Lähteenvuo, M., De Koning, M.B., Morgenroth, C., Müderrisoğlu, A., Oviedo-salcedo, T., Schreiter, S., Repo-tiihonen, E., Tuppurainen, H., Veereschild, M., Veerman, S.R.T., Cohen, D., de Vos, M., Bogers, J.P.A.M., Anıl Yağcıoğlu, A.E., Tiihonen, J., Ripke, S., Bousman, C.A., Van Beek, H, van der Horst, M., Van Eijk, K., Ertuğrul, A., Yoca, G., Görlitz, T., Grootens, K., Leucht, S., Narang, A., Schneider-thoma, J., Kahn, R.S., Bekema, E., Kleymann, P., Alizadeh, B.Z., van Amelsvoort, T., Cahn, W., de Haan, L., Schirmbeck, F., Simons, C.J.P., van Os, J., Rutten, B., van Winkel, R., Lin, B.D., Pinzón-Espinosa, J., Blouzard, E., Van Der Horst, M.Z., Okhuijsen-pfeifer, C., Van Eijk, K.R., Guloksuz, S., Peyrot, W.J., Luykx, J.J., Hasan, A., Wagner, E., Pantelis, C., Everall, I.P., Ayhan, Y., Babaoğlu, M.O., Bak, M., Alink, W., Beld, E, Bouhuis, A., Edlinger, M., Erdoğan, I.M., Gutwinski, S., Hallikainen, T., Jeger-land, E., Lähteenvuo, M., De Koning, M.B., Morgenroth, C., Müderrisoğlu, A., Oviedo-salcedo, T., Schreiter, S., Repo-tiihonen, E., Tuppurainen, H., Veereschild, M., Veerman, S.R.T., Cohen, D., de Vos, M., Bogers, J.P.A.M., Anıl Yağcıoğlu, A.E., Tiihonen, J., Ripke, S., Bousman, C.A., Van Beek, H, van der Horst, M., Van Eijk, K., Ertuğrul, A., Yoca, G., Görlitz, T., Grootens, K., Leucht, S., Narang, A., Schneider-thoma, J., Kahn, R.S., Bekema, E., Kleymann, P., Alizadeh, B.Z., van Amelsvoort, T., Cahn, W., de Haan, L., Schirmbeck, F., Simons, C.J.P., van Os, J., Rutten, B., and van Winkel, R.

Abstract

Importance: Predictors consistently associated with psychosis liability and course of illness in schizophrenia (SCZ) spectrum disorders (SSD), including the need for clozapine treatment, are lacking. Longitudinally ascertained medication use may empower studies examining associations between polygenic risk scores (PRSs) and pharmacotherapy choices. Objective: To examine associations between PRS-SCZ loading and groups with different liabilities to SSD (individuals with SSD taking clozapine, individuals with SSD taking other antipsychotics, their parents and siblings, and unrelated healthy controls) and between PRS-SCZ and the likelihood of receiving a prescription of clozapine relative to other antipsychotics. Design, Setting, and Participants: This genetic association study was a multicenter, observational cohort study with 6 years of follow-up. Included were individuals diagnosed with SSD who were taking clozapine or other antipsychotics, their parents and siblings, and unrelated healthy controls. Data were collected from 2004 until 2021 and analyzed between October 2021 and September 2022. Exposures: Polygenic risk scores for SCZ. Main Outcomes and Measures: Multinomial logistic regression was used to examine possible differences between groups by computing risk ratios (RRs), ie, ratios of the probability of pertaining to a particular group divided by the probability of healthy control status. We also computed PRS-informed odd ratios (ORs) for clozapine use relative to other antipsychotics. Results: Polygenic risk scores for SCZ were generated for 2344 participants (mean [SD] age, 36.95 years [14.38]; 994 female individuals [42.4%]) who remained after quality control screening (557 individuals with SSD taking clozapine, 350 individuals with SSD taking other antipsychotics during the 6-year follow-up, 542 parents and 574 siblings of individuals with SSD, and 321 unrelated healthy controls). All RR

Published
2023

13. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

Author

Velthorst E., Mollon J., Murray R. M., de Haan L., Germeys I. M., Glahn D. C., Arango C., van der Ven E., Di Forti M., Bernardo M., Guloksuz S., Delespaul P., Mezquida G., Amoretti S., Bobes J., Saiz P. A., Garcia-Portilla M. P., Santos J. L., Jimenez-Lopez E., Sanjuan J., Aguilar E. J., Arrojo M., Carracedo A., Lopez G., Gonzalez-Penas J., Parellada M., Atbasoglu C., Saka M. C., Ucok A., Alptekin K., Akdede B., Binbay T., Altinyazar V., Ulas H., Yalincetin B., Gumus-Akay G., Beyaz B. C., Soygur H., Cankurtaran E. S., Kaymak S. U., Maric N. P., Mihaljevic M. M., Petrovic S. A., Mirjanic T., Del-Ben C. M., Ferraro L., Gayer-Anderson C., Jones P. B., Jongsma H. E., Kirkbride J. B., La Cascia C., Lasalvia A., Tosato S., Llorca P. -M., Menezes P. R., Morgan C., Quattrone D., Menchetti M., Selten J. -P., Szoke A., Tarricone I., Tortelli A., McGuire P., Valmaggia L., Kempton M. J., van der Gaag M., Riecher-Rossler A., Bressan R. A., Barrantes-Vidal N., Nelson B., McGorry P., Pantelis C., Krebs M. -O., Ruhrmann S., Sachs G., Rutten B. P. F., van Os J., Alizadeh B. Z., van Amelsvoort T., Bartels-Velthuis A. A., Bruggeman R., van Beveren N. J., Luykx J. J., Cahn W., Simons C. J. P., Kahn R. S., Schirmbeck F., van Winkel R., Calem M., Tognin S., Modinos G., Pisani S., Kraan T. C., van Dam D. S., Burger N., Amminger G. P., Politis A., Goodall J., Borgwardt S., Studerus E., Gadelha A., Brietzke E., Asevedo G., Asevedo E., Zugman A., Dominguez-Martinez T., Monsonet M., Cristobal-Narvaez P., Racioppi A., Kwapil T. R., Kazes M., Daban C., Bourgin J., Gay O., Mam-Lam-Fook C., Nordholm D., Rander L., Krakauer K., Glenthoj L. B., Glenthoj B., Gebhard D., Arnhold J., Klosterkotter J., Lasser I., Winklbaur B., Reichenberg A., Velthorst E., Mollon J., Murray R.M., de Haan L., Germeys I.M., Glahn D.C., Arango C., van der Ven E., Di Forti M., Bernardo M., Guloksuz S., Delespaul P., Mezquida G., Amoretti S., Bobes J., Saiz P.A., Garcia-Portilla M.P., Santos J.L., Jimenez-Lopez E., Sanjuan J., Aguilar E.J., Arrojo M., Carracedo A., Lopez G., Gonzalez-Penas J., Parellada M., Atbasoglu C., Saka M.C., Ucok A., Alptekin K., Akdede B., Binbay T., Altinyazar V., Ulas H., Yalincetin B., Gumus-Akay G., Beyaz B.C., Soygur H., Cankurtaran E.S., Kaymak S.U., Maric N.P., Mihaljevic M.M., Petrovic S.A., Mirjanic T., Del-Ben C.M., Ferraro L., Gayer-Anderson C., Jones P.B., Jongsma H.E., Kirkbride J.B., La Cascia C., Lasalvia A., Tosato S., Llorca P.-M., Menezes P.R., Morgan C., Quattrone D., Menchetti M., Selten J.-P., Szoke A., Tarricone I., Tortelli A., McGuire P., Valmaggia L., Kempton M.J., van der Gaag M., Riecher-Rossler A., Bressan R.A., Barrantes-Vidal N., Nelson B., McGorry P., Pantelis C., Krebs M.-O., Ruhrmann S., Sachs G., Rutten B.P.F., van Os J., Alizadeh B.Z., van Amelsvoort T., Bartels-Velthuis A.A., Bruggeman R., van Beveren N.J., Luykx J.J., Cahn W., Simons C.J.P., Kahn R.S., Schirmbeck F., van Winkel R., Calem M., Tognin S., Modinos G., Pisani S., Kraan T.C., van Dam D.S., Burger N., Amminger G.P., Politis A., Goodall J., Borgwardt S., Studerus E., Gadelha A., Brietzke E., Asevedo G., Asevedo E., Zugman A., Dominguez-Martinez T., Monsonet M., Cristobal-Narvaez P., Racioppi A., Kwapil T.R., Kazes M., Daban C., Bourgin J., Gay O., Mam-Lam-Fook C., Nordholm D., Rander L., Krakauer K., Glenthoj L.B., Glenthoj B., Gebhard D., Arnhold J., Klosterkotter J., Lasser I., Winklbaur B., Reichenberg A., RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Neurosciences, Psychiatry, Clinical Developmental Psychology, World Health Organization (WHO) Collaborating Center, Life Course Epidemiology (LCE), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Clinical Cognitive Neuropsychiatry Research Program (CCNP), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Adult Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, and Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
0301 basic medicine, validity, medicine.medical_treatment, CHILDHOOD, Neuropsychological Tests, FAMÍLIA, episode, Cognition, 0302 clinical medicine, DEFICITS, Settore MED/48 -Scienze Infermierist. e Tecn. Neuro-Psichiatriche e Riabilitat, Medicine, Cognitive impairment, Psychiatry, Symptom severity, Cannabis use, IMPAIRMENT, ABILITY, Psychiatry and Mental health, Schizophrenia, RELIABILITY, Neuropsychological Test, Life Sciences & Biomedicine, Human, Clinical psychology, Adult, Biochemistry & Molecular Biology, impairment, schizophrenia-patients, ability, GENETIC RISK, Psychotic Disorder, SCHIZOPHRENIA-PATIENTS, 03 medical and health sciences, Cellular and Molecular Neuroscience, SDG 3 - Good Health and Well-being, Settore M-PSI/08 - Psicologia Clinica, Humans, In patient, Cognitive skill, VALIDITY, Antipsychotic, Molecular Biology, Settore MED/25 - Psichiatria, Aged, Cross-Sectional Studie, DECLINE, Science & Technology, reliability, business.industry, Working memory, Siblings, Neurosciences, Diagnostic markers, medicine.disease, Cross-Sectional Studies, 030104 developmental biology, deficits, Psychotic Disorders, PSYCHOSIS, COGNITION, MULTICENTRIC STUDY, Neurosciences & Neurology, business, EPISODE, 030217 neurology & neurosurgery
Abstract

The European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (EUGEI); The Spanish sample was supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024) (...), Velthorst, E., Mollon, J., Murray, R.M., de Haan, L., Germeys, I.M., Glahn, D.C., Arango, C., van der Ven, E., Di Forti, M., Bernardo, M., Guloksuz, S., Delespaul, P., Mezquida, G., Amoretti, S., Bobes, J., Saiz, P.A., García-Portilla, M.P., Santos, J.L., Jiménez-López, E., Sanjuan, J., Aguilar, E.J., Arrojo, M., Carracedo, A., López, G., González-Peñas, J., Parellada, M., Atbaşoğlu, C., Saka, M.C., Üçok, A., Alptekin, K., Akdede, B., Binbay, T., Altınyazar, V., Ulaş, H., Yalınçetin, B., Gümüş-Akay, G., Beyaz, B.C., Soygür, H., Cankurtaran, E.Ş., Kaymak, S.U., Maric, N.P., Mihaljevic, M.M., Petrovic, S.A., Mirjanic, T., Del-Ben, C.M., Ferraro, L., Gayer-Anderson, C., Jones, P.B., Jongsma, H.E., Kirkbride, J.B., La Cascia, C., Lasalvia, A., Tosato, S., Llorca, P.-M., Menezes, P.R., Morgan, C., Quattrone, D., Menchetti, M., Selten, J.-P., Szöke, A., Tarricone, I., Tortelli, A., McGuire, P., Valmaggia, L., Kempton, M.J., van der Gaag, M., Riecher-Rössler, A., Bressan, R.A., Barrantes-Vidal, N., Nelson, B., McGorry, P., Pantelis, C., Krebs, M.-O., Ruhrmann, S., Sachs, G., Rutten, B.P.F., van Os, J., Alizadeh, B.Z., van Amelsvoort, T., Bartels-Velthuis, A.A., Bruggeman, R., van Beveren, N.J., Luykx, J.J., Cahn, W., Simons, C.J.P., Kahn, R.S., Schirmbeck, F., van Winkel, R., Calem, M., Tognin, S., Modinos, G., Pisani, S., Kraan, T.C., van Dam, D.S., Burger, N., Amminger, G.P., Politis, A., Goodall, J., Borgwardt, S., Studerus, E., Gadelha, A., Brietzke, E., Asevedo, G., Asevedo, E., Zugman, A., Domínguez-Martínez, T., Monsonet, M., Cristóbal-Narváez, P., Racioppi, A., Kwapil, T.R., Kazes, M., Daban, C., Bourgin, J., Gay, O., Mam-Lam-Fook, C., Nordholm, D., Rander, L., Krakauer, K., Glenthøj, L.B., Glenthøj, B., Gebhard, D., Arnhold, J., Klosterkötter, J., Lasser, I., Winklbaur, B., Reichenberg, A., EU-GEI High Risk Study

Published
2021

19. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders

Author

Okhuijsen-Pfeifer, C., van der Horst, M. Z., Bousman, C. A., Lin, B., van Eijk, K. R., Ripke, S., Ayhan, Y., Babaoglu, M. O., Bak, M., Alink, W., van Beek, H., Beld, E., Bouhuis, A., Edlinger, M., Erdogan, I. M., Ertuğrul, A., Yoca, G., Everall, I. P., Görlitz, T., van Amelsvoort, T., Bartels-Velthuis, A. A., Bruggeman, R., Cahn, W., Guloksuz, S., de Haan, L., Kahn, R. S., Schirmbeck, F., Simons, C. J. P., van Os, J., Alizadeh, B. Z., Luykx, J. J., Rutten, B. P. F., van Winkel, R., Grootens, K. P., Gutwinski, S., Hallikainen, T., Jeger-Land, E., de Koning, M., Lähteenvuo, M., Legge, S. E., Leucht, S., Morgenroth, C., Müderrisoğlu, A., Narang, A., Pantelis, C., Pardiñas, A. F., Oviedo-Salcedo, T., Schneider-Thoma, J., Schreiter, S., Repo-Tiihonen, E., Tuppurainen, H., Veereschild, M., Veerman, S., de Vos, M., Wagner, E., Cohen, D., Bogers, J. P. A. M., Walters, J. T. R., Yağcıoğlu, A. E. Anil, Tiihonen, J., Hasan, A., Clinical Cognitive Neuropsychiatry Research Program (CCNP), Life Course Epidemiology (LCE), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Psychiatrie & Neuropsychologie, RS: MHeNs - R3 - Neuroscience, Adult Psychiatry, APH - Mental Health, ANS - Complex Trait Genetics, and ANS - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
POLYGENIC RISK SCORE, GENETIC RISK, N-DESMETHYLCLOZAPINE, Schizophrenia/chemically induced, Cytochrome P-450 CYP1A2/genetics, Cellular and Molecular Neuroscience, Cytochrome P-450 CYP1A2, Humans, ddc:610, CYP2C19, BRAIN, Clozapine, POLYMORPHISMS, Biological Psychiatry, IDENTIFICATION, PHARMACOGENETICS, CYTOCHROME-P450, Clozapine/therapeutic use, Cytochrome P-450 CYP2C19, Psychiatry and Mental health, Cytochrome P-450 CYP2D6, Schizophrenia, Cytochrome P-450 CYP2C19/genetics, Antipsychotic Agents/therapeutic use, Cytochrome P-450 CYP2D6/genetics, PHARMACOLOGICAL-TREATMENT, Antipsychotic Agents, Genome-Wide Association Study
Abstract

Clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia. However, response is highly variable and possible genetic underpinnings of this variability remain unknown. Here, we performed polygenic risk score (PRS) analyses to estimate the amount of variance in symptom severity among clozapine-treated patients explained by PRSs (R2) and examined the association between symptom severity and genotype-predicted CYP1A2, CYP2D6, and CYP2C19 enzyme activity. Genome-wide association (GWA) analyses were performed to explore loci associated with symptom severity. A multicenter cohort of 804 patients (after quality control N = 684) with schizophrenia spectrum disorder treated with clozapine were cross-sectionally assessed using the Positive and Negative Syndrome Scale and/or the Clinical Global Impression-Severity (CGI-S) scale. GWA and PRS regression analyses were conducted. Genotype-predicted CYP1A2, CYP2D6, and CYP2C19 enzyme activities were calculated. Schizophrenia-PRS was most significantly and positively associated with low symptom severity (p = 1.03 × 10−3; R2 = 1.85). Cross-disorder-PRS was also positively associated with lower CGI-S score (p = 0.01; R2 = 0.81). Compared to the lowest tertile, patients in the highest schizophrenia-PRS tertile had 1.94 times (p = 6.84×10−4) increased probability of low symptom severity. Higher genotype-predicted CYP2C19 enzyme activity was independently associated with lower symptom severity (p = 8.44×10−3). While no locus surpassed the genome-wide significance threshold, rs1923778 within NFIB showed a suggestive association (p = 3.78×10−7) with symptom severity. We show that high schizophrenia-PRS and genotype-predicted CYP2C19 enzyme activity are independently associated with lower symptom severity among individuals treated with clozapine. Our findings open avenues for future pharmacogenomic projects investigating the potential of PRS and genotype-predicted CYP-activity in schizophrenia.

Published
2022

20. Brain charts for the human lifespan

Author

Armin Raznahan, Eric Courchesne, Andrea Parolin Jackowski, Kamen A. Tsvetanov, Cameron T. Ellis, R.C. Gur, Bin Bae J, Park Mtm, Pedro A. Valdes-Sosa, Simon N. Vandekar, Jacob W. Vogel, Juan Zhou, Machteld Marcelis, Kiho Im, Patricia Ellen Grant, Minhui Ouyang, Blesa Cabez M, Michael V. Lombardo, Sarah E. Morgan, James P. Boardman, Adamson C, Calhoun Vd, Delarue M, James H. Cole, Pichet Binette A, Roberto Toro, David H. Rowitch, Nynke A. Groenewold, Kevin M. Anderson, David T.W. Jones, Michael Schöll, Wang Ys, Aiden Corvin, R.E. Gur, Damien A. Fair, Gareth Ball, Herma Lina Schaare, Andrew Zalesky, Evdokia Anagnostou, Michael J. Meaney, Taki Y, Gareth J. Sullivan, Warrier, Petra E. Vértes, Chixiang Chen, Lisa T. Eyler, Wei Liao, Tomáš Paus, Jeremy A. Elman, Phillip McGuire, Hisham Ziauddeen, William S. Kremen, Etienne Vachon-Presseau, E.T. Bullmore, Christophe Tzourio, White, Hammill Cf, Mothersill D, Richard N. Henson, Jiang Qiu, Duncan E. Astle, Fabrice Crivello, Paul C. Fletcher, Chertavian C, Kim K, Jennifer Crosbie, Russell Schachar, Gabriel A. Devenyi, Manfred G. Kitzbichler, Tianye Jia, Trey Hedden, Sang Jae Lee, Ross D. Markello, Silke Kern, Ian M. Goodyer, Keith A. Johnson, Frauke Beyer, Bernard Mazoyer, A. Heinz, Sylvane Desrivières, Rosenberg, Gary Donohoe, Ong Mq, Alexander D. Edwards, Dan J. Stein, Nenad Medic, Zuo Xn, Travis T. Mallard, Peter Fonagy, Lindsay W. Victoria, Ingmar Skoog, Avram J. Holmes, Jason P. Lerch, Jed T. Elison, Jianfu Li, John H. Gilmore, Rosemary Holt, Caitlin K. Rollins, Carol E. Franz, Pedro Mario Pan, Saashi A Bedford, Yang N, Jonathan C Ipser, Richard A. I. Bethlehem, Tuulari Jj, Stolicyn A, Hua Huang, Bratislav Misic, Conor Liston, Ayub M, Lisa Ronan, Yeo Bt, Sophie Adler, Charles J. Lynch, Faith M. Gunning, Konrad Wagstyl, M. Mallar Chakravarty, John Suckling, Theodore D. Satterthwaite, Bharath Holla, Yap Seng Chong, Jinglei Lv, Jakob Seidlitz, Niall J Bourke, Xinlei Qian, Simon Baron-Cohen, Cynthia M. Ortinau, Deirel Paz Linares, Thyreau B, René S. Kahn, Aaron P. Schultz, Vanessa Cropley, Eric Westman, Mitchell Valdés-Sosa, Rik Ossenkoppele, André Zugman, Hasse Karlsson, Sylvia Villeneuve, Katja Heuer, Di Biase Ma, Margaret L. Westwater, Sofie L. Valk, David J. Sharp, Brigitte Landeau, Matthew Borzage, Kirsten A. Donald, Timothy Rittman, Richard Beare, Giovanni Abrahão Salum, Gunter Schumann, Ryuta Kawashima, Romero-Garcia R, John Blangero, Yun Hj, Russel T. Shinohara, Nicolas Crossley, Simon K. Warfield, Karen Pierce, George S. Alexopoulos, Katharine Dunlop, David C. Glahn, Francois Lalonde, Anqi Qiu, Lana Vasung, Gaël Chételat, Lídice Galán-García, Clifford R. Jack, Reisa A. Sperling, Anna Zettergren, Elizabeth Kelley, Arno Villringer, Andrea Mechelli, Benegal, Aaron Alexander-Bloch, Nicholas B. Turk-Browne, van Amelsvoort T, John D. Lewis, Heather C. Whalley, A. V. Witte, Zdenka Pausova, Joel T. Nigg, Heather J. Zar, Raymond J. Dolan, Christopher D. Smyser, Jay N. Giedd, Lena Palaniyappan, Ali Gholipour, Areces-Gonzalez A, Peter B. Jones, Jacqueline Hoare, Oskar Hansson, Linnea Karlsson, C Pantelis, Paly L, Bonnie Auyeung, Jorge Bosch-Bayard, Bethlehem, Richard [0000-0002-0714-0685], White, Simon [0000-0001-8642-7037], Astle, Duncan [0000-0002-7042-5392], Baron-Cohen, Simon [0000-0001-9217-2544], Henson, Rik [0000-0002-0712-2639], Jones, Peter [0000-0002-0387-880X], Kitzbichler, Manfred [0000-0002-4494-0753], Rittman, Timothy [0000-0003-1063-6937], Rowitch, David [0000-0002-0079-0060], Tsvetanov, Kamen A. [0000-0002-3178-6363], Westwater-Wozniak, Margaret [0000-0002-2918-0979], Ziauddeen, Hisham [0000-0003-4044-1719], Apollo - University of Cambridge Repository, British Academy, Autism Research Trust, National Institute of Mental Health (US), UK Research and Innovation, Medical Research Council (UK), National Institute for Health and Care Research (US), Wellcome Trust, University of Cambridge, Cambridge Biomedical Research Centre, University of Cambridge [UK] (CAM), University of Pennsylvania, Yale University [New Haven], Institut des Maladies Neurodégénératives [Bordeaux] (IMN), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie et imagerie des troubles neurologiques (PhIND), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Génétique humaine et fonctions cognitives - Human Genetics and Cognitive Functions (GHFC (UMR_3571 / U-Pasteur_1)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Child and Adolescent Psychiatry Department [AP- HP Hôpital Robert Debré], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Neuroscience - Department of Neuroscience, Centre de Recherche Interdisciplinaire / Center for Research and Interdisciplinarity [Paris, France] (CRI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Psychiatrie & Neuropsychologie, RS: MHeNs - R2 - Mental Health, MUMC+: MA Med Staf Spec Psychiatrie (9), Neurology, Amsterdam Neuroscience - Neurodegeneration, 3R-BRAIN, AIBL, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Repository Without Borders Investigators, CALM Team, Cam-CAN, CCNP, COBRE, cVEDA, ENIGMA Developmental Brain Age Working Group, Developing Human Connectome Project, FinnBrain, Harvard Aging Brain Study, IMAGEN, KNE96, The Mayo Clinic Study of Aging, NSPN, POND, The PREVENT-AD Research Group, VETSA, [Bethlehem, R. A. I.] Univ Cambridge, Dept Psychiat, Autism Res Ctr, Cambridge, England, [Auyeung, B.] Univ Cambridge, Dept Psychiat, Autism Res Ctr, Cambridge, England, [Baron-Cohen, S.] Univ Cambridge, Dept Psychiat, Autism Res Ctr, Cambridge, England, [Bedford, S. A.] Univ Cambridge, Dept Psychiat, Autism Res Ctr, Cambridge, England, [Holt, R.] Univ Cambridge, Dept Psychiat, Autism Res Ctr, Cambridge, England, [Lombardo, M. V.] Univ Cambridge, Dept Psychiat, Autism Res Ctr, Cambridge, England, [Bethlehem, R. A. I.] Univ Cambridge, Dept Psychiat, Brain Mapping Unit, Cambridge, England, [Kitzbichler, M. G.] Univ Cambridge, Dept Psychiat, Brain Mapping Unit, Cambridge, England, [Seidlitz, J.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA, [Vogel, J. W.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA, [Gur, R. E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA, [Gur, R. C.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA, [Jackowski, A. P.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA, [Satterthwaite, T. D.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA, [Alexander-Bloch, A. F.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA, [Seidlitz, J.] Childrens Hosp Philadelphia, Dept Child & Adolescent Psychiat & Behav Sci, Philadelphia, PA 19104 USA, [Alexander-Bloch, A. F.] Childrens Hosp Philadelphia, Dept Child & Adolescent Psychiat & Behav Sci, Philadelphia, PA 19104 USA, [Seidlitz, J.] Childrens Hosp Philadelphia & Penn Med, Lifespan Brain Inst, Philadelphia, PA USA, [Chertavian, C.] Childrens Hosp Philadelphia & Penn Med, Lifespan Brain Inst, Philadelphia, PA USA, [Gur, R. E.] Childrens Hosp Philadelphia & Penn Med, Lifespan Brain Inst, Philadelphia, PA USA, [Gur, R. C.] Childrens Hosp Philadelphia & Penn Med, Lifespan Brain Inst, Philadelphia, PA USA, [Alexander-Bloch, A. F.] Childrens Hosp Philadelphia & Penn Med, Lifespan Brain Inst, Philadelphia, PA USA, [White, S. R.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Goodyer, I. M.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Henson, R. N.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Jones, P. B.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Kitzbichler, M. G.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Medic, N.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Morgan, S. E.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Romero-Garcia, R.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Ronan, L.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Suckling, J.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Vertes, P. E.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Warrier, V.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Westwater, M. L.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Ziauddeen, H.] Univ Cambridge, Dept Psychiat, Cambridge, England, [Bullmore, E. T.] Univ Cambridge, Dept Psychiat, Cambridge, England, [White, S. R.] Univ Cambridge, MRC Biostat Unit, Cambridge, England, [Vogel, J. W.] Univ Penn, Lifespan Informat & Neuroimaging Ctr, Philadelphia, PA 19104 USA, [Satterthwaite, T. D.] Univ Penn, Lifespan Informat & Neuroimaging Ctr, Philadelphia, PA 19104 USA, [Anderson, K. M.] Yale Univ, Dept Psychol, New Haven, CT USA, [Ellis, C. T.] Yale Univ, Dept Psychol, New Haven, CT USA, [Turk-Browne, N. B.] Yale Univ, Dept Psychol, New Haven, CT USA, [Adamson, C.] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia, [Ball, G.] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia, [Beare, R.] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia, [Jackowski, A. P.] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia, [Adamson, C.] Monash Univ, Dept Med, Melbourne, Vic, Australia, [Beare, R.] Monash Univ, Dept Med, Melbourne, Vic, Australia, [Adler, S.] UCL Great Ormond St Inst Child Hlth, London, England, [Alexopoulos, G. S.] Weill Cornell Med, Dept Psychiat, Weill Cornell Inst Geriatr Psychiat, New York, NY USA, [Anagnostou, E.] Univ Toronto, Dept Pediat, Toronto, ON, Canada, [Anagnostou, E.] Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada, [Pierce, K.] Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada, [Areces-Gonzalez, A.] Univ Elect Sci & Technol China, MOE Key Lab NeuroInformat, Clin Hosp, Chengdu Brain Sci Inst, Chengdu, Peoples R China, [Paz-Linares, D.] Univ Elect Sci & Technol China, MOE Key Lab NeuroInformat, Clin Hosp, Chengdu Brain Sci Inst, Chengdu, Peoples R China, [Areces-Gonzalez, A.] Univ Pinar del Rio Hermanos Saiz Montes de Oca, Pinar Del Rio, Cuba, [Astle, D. E.] Univ Cambridge, MRC Cognit & Brain Sci Unit, Cambridge, England, [Henson, R. N.] Univ Cambridge, MRC Cognit & Brain Sci Unit, Cambridge, England, [Whalley, H. C.] Univ Cambridge, MRC Cognit & Brain Sci Unit, Cambridge, England, [Auyeung, B.] Univ Edinburgh, Sch Philosophy Psychol & Language Sci, Dept Psychol, Edinburgh, Midlothian, Scotland, [Pausova, Z.] Univ Edinburgh, Sch Philosophy Psychol & Language Sci, Dept Psychol, Edinburgh, Midlothian, Scotland, [Ayub, M.] Queens Univ, Dept Psychiat, Ctr Neurosci Studies, Kingston, ON, Canada, [Ayub, M.] UCL, Mental Hlth Neurosci Res Dept, Div Psychiat, London, England, [Bae, J.] Seoul Natl Univ, Bundang Hosp, Dept Neuropsychiat, Seongnam, South Korea, [Ball, G.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia, [Baron-Cohen, S.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge Lifetime Asperger Syndrome Serv CLASS, Cambridge, England, [Benegal, V.] Natl Inst Mental Hlth & Neurosci NIMHANS, Ctr Addict Med, Bengaluru, India, [Beyer, F.] Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Germany, [Villringer, A.] Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Germany, [Witte, A. V.] Max Planck Inst Human Cognit & Brain Sci, Dept Neurol, Leipzig, Germany, [Blangero, J.] Univ Texas Rio Grande Valley, South Texas Diabet & Obes Inst, Dept Human Genet, Edinburg, TX USA, [Blesa Cabez, M.] Univ Edinburgh, MRC Ctr Reprod Hlth, Edinburgh, Midlothian, Scotland, [Boardman, J. P.] Univ Edinburgh, MRC Ctr Reprod Hlth, Edinburgh, Midlothian, Scotland, [Sullivan, G.] Univ Edinburgh, MRC Ctr Reprod Hlth, Edinburgh, Midlothian, Scotland, [Borzage, M.] Univ Southern Calif, Childrens Hosp Los Angeles, Keck Sch Med, Fetal & Neonatal Inst,Div Neonatol,Dept Pediat, Los Angeles, CA 90007 USA, [Bosch-Bayard, J. F.] Montreal Neurol Inst, Ludmer Ctr Neuroinformat & Mental Hlth, McGill Ctr Integrat Neurosci, Montreal, PQ, Canada, [Bosch-Bayard, J. F.] McGill Univ, Montreal, PQ, Canada, [Chakravarty, M. M.] McGill Univ, Montreal, PQ, Canada, [Bourke, N.] Imperial Coll London, Dept Brain Sci, London, England, [Sharp, D.] Imperial Coll London, Dept Brain Sci, London, England, [Alexander-Bloch, A. F.] Imperial Coll London, Dept Brain Sci, London, England, [Bourke, N.] Dementia Res Inst, Care Res & Technol Ctr, London, England, [Calhoun, V. D.] Georgia State Univ, Triinst Ctr Translat Res Neuroimaging & Data Sci, Georgia Inst Technol, Atlanta, GA 30303 USA, [Calhoun, V. D.] Emory Univ, Atlanta, GA 30322 USA, [Chakravarty, M. M.] Douglas Mental Hlth Univ Inst, Cerebral Imaging Ctr, Comp Brain Anat CoBrA Lab, Montreal, PQ, Canada, [Chen, C.] Univ Penn, Penn Stat Imaging & Visualizat Ctr, Dept Biostat Epidemiol & Informat, Perelman Sch Med, Philadelphia, PA 19104 USA, [Shinohara, R. T.] Univ Penn, Penn Stat Imaging & Visualizat Ctr, Dept Biostat Epidemiol & Informat, Perelman Sch Med, Philadelphia, PA 19104 USA, [Chetelat, G.] Normandie Univ, PhIND Physiopathol & Imaging Neurol Disorders, Inst Blood & Brain Caen Normandie, UNICAEN,INSERM,U1237, Caen, France, [Delarue, M.] Normandie Univ, PhIND Physiopathol & Imaging Neurol Disorders, Inst Blood & Brain Caen Normandie, UNICAEN,INSERM,U1237, Caen, France, [Landeau, B.] Normandie Univ, PhIND Physiopathol & Imaging Neurol Disorders, Inst Blood & Brain Caen Normandie, UNICAEN,INSERM,U1237, Caen, France, [Paly, L.] Normandie Univ, PhIND Physiopathol & Imaging Neurol Disorders, Inst Blood & Brain Caen Normandie, UNICAEN,INSERM,U1237, Caen, France, [Chong, Y. S.] Agcy Sci Technol & Res, Singapore Inst Clin Sci, Singapore, Singapore, [Chong, Y. S.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynaecol, Singapore, Singapore, [Cole, J. H.] UCL, Ctr Med Image Comp CMIC, London, England, [Cole, J. H.] UCL, Dementia Res Ctr DRC, London, England, [Corvin, A.] Trinity Coll Dublin, Dept Psychiat, Dublin, Ireland, [Costantino, M.] Douglas Mental Hlth Univ Inst, Cerebral Imaging Ctr, Verdun, PQ, Canada, [Costantino, M.] McGill Univ, Undergrad Program Neurosci, Montreal, PQ, Canada, [Courchesne, E.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA, [Courchesne, E.] Univ Calif San Diego, Autism Ctr Excellence, San Diego, CA 92103 USA, [Crivello, F.] Univ Bordeaux, Inst Neurodegenerat Disorders, CNRS UMR5293, CEA, Bordeaux, France, [Mazoyer, B.] Univ Bordeaux, Inst Neurodegenerat Disorders, CNRS UMR5293, CEA, Bordeaux, France, [Cropley, V. L.] Univ Melbourne, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia, [Di Biase, M. A.] Univ Melbourne, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia, [Lv, J.] Univ Melbourne, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia, [Zalesky, A.] Univ Melbourne, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia, [Hammill, C. F.] Hosp Sick Children, Toronto, ON, Canada, [Schachar, R. J.] Hosp Sick Children, Toronto, ON, Canada, [Crossley, N.] Pontificia Univ Catolica Chile, Sch Med, Dept Psychiat, Santiago, Chile, [Crossley, N.] Kings Coll London, Dept Psychosis Studies, Inst Psychiat Psychol & Neurosci, London, England, [McGuire, P.] Kings Coll London, Dept Psychosis Studies, Inst Psychiat Psychol & Neurosci, London, England, [Crossley, N.] Inst Milenio Intelligent Healthcare Engn, Santiago, Chile, [Delorme, R.] Robert Debre Univ Hosp, AP HP, Child & Adolescent Psychiat Dept, Paris, France, [Delorme, R.] Inst Pasteur, Human Genet & Cognit Funct, Paris, France, [Desrivieres, S.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Social Genet & Dev Psychiat Ctr, London, England, [Devenyi, G. A.] Douglas Mental Hlth Univ Inst, McGill Dept Psychiat, Cerebral Imaging Ctr, Montreal, PQ, Canada, [Devenyi, G. A.] McGill Univ, Dept Psychiat, Montreal, PQ, Canada, [Di Biase, M. A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA, [Dolan, R.] UCL, Max Planck UCL Ctr Computat Psychiat & Ageing Res, London, England, [Dolan, R.] Wellcome Ctr Human Neuroimaging, London, England, [Wagstyl, K.] Wellcome Ctr Human Neuroimaging, London, England, [Donald, K. A.] Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, Div Dev Paediat, Cape Town, South Africa, [Donald, K. A.] Univ Cape Town, Neurosci Inst, Cape Town, South Africa, [Groenewold, N. A.] Univ Cape Town, Neurosci Inst, Cape Town, South Africa, [Donohoe, G.] Natl Univ Ireland Galway, Sch Psychol, Ctr Neuroimaging Cognit & Genom NICOG, Galway, Ireland, [Dunlop, K.] Weill Cornell Med, Dept Psychiat, Weil Family Brain & Mind Res Inst, New York, NY USA, [Lynch, C.] Weill Cornell Med, Dept Psychiat, Weil Family Brain & Mind Res Inst, New York, NY USA, [Edwards, A. D.] Kings Coll London, Ctr Dev Brain, London, England, [Edwards, A. D.] Evelina London Childrens Hosp, London, England, [Edwards, A. D.] MRC Ctr Neurodev Disorders, London, England, [Elison, J. T.] Univ Minnesota, Mason Inst Dev Brain, Dept Pediat, Inst Child Dev, Minneapolis, MN USA, [Fair, D. A.] Univ Minnesota, Mason Inst Dev Brain, Dept Pediat, Inst Child Dev, Minneapolis, MN USA, [Feczko, E.] Univ Minnesota, Mason Inst Dev Brain, Dept Pediat, Inst Child Dev, Minneapolis, MN USA, [Ellis, C. T.] Haskins Labs Inc, New Haven, CT USA, [Elman, J. A.] Univ Calif San Diego, Dept Psychiat, Ctr Behav Genet Aging, La Jolla, CA 92093 USA, [Franz, C. E.] Univ Calif San Diego, Dept Psychiat, Ctr Behav Genet Aging, La Jolla, CA 92093 USA, [Kremen, W. S.] Univ Calif San Diego, Dept Psychiat, Ctr Behav Genet Aging, La Jolla, CA 92093 USA, [Eyler, L.] VA San Diego Healthcare, Desert Pacific Mental Illness Res Educ & Clin Ctr, San Diego, CA USA, [Eyler, L.] Univ Calif San Diego, Dept Psychiat, Los Angeles, CA USA, [Fletcher, P. C.] Univ Cambridge, Dept Psychiat, Cambridge Biomed Campus, Cambridge, England, [Fletcher, P. C.] Wellcome Trust MRC Inst Metab Sci, Cambridge Biomed Campus, Cambridge, England, [Fletcher, P. C.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England, [Jones, P. B.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England, [Suckling, J.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England, [Ziauddeen, H.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England, [Fonagy, P.] UCL, Dept Clin Educ & Hlth Psychol, London, England, [Fonagy, P.] Anna Freud Natl Ctr Children & Families, London, England, [Galan-Garcia, L.] Cuban Ctr Neurosci, Havana, Cuba, [Valdes-Sosa, M. J.] Cuban Ctr Neurosci, Havana, Cuba, [Gholipour, A.] Boston Childrens Hosp, Computat Radiol Lab, Boston, MA USA, [Warfield, S. K.] Boston Childrens Hosp, Computat Radiol Lab, Boston, MA USA, [Giedd, J.] Univ Calif San Diego, Dept Child & Adolescent Psychiat, San Diego, CA 92103 USA, [Giedd, J.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA, [Gilmore, J. H.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC 27515 USA, [Glahn, D. C.] Boston Childrens Hosp, Dept Psychiat, Boston, MA USA, [Im, K.] Boston Childrens Hosp, Dept Psychiat, Boston, MA USA, [Mathias, S. R.] Boston Childrens Hosp, Dept Psychiat, Boston, MA USA, [Rodrigue, A.] Boston Childrens Hosp, Dept Psychiat, Boston, MA USA, [Glahn, D. C.] Harvard Med Sch, Boston, MA 02115 USA, [Im, K.] Harvard Med Sch, Boston, MA 02115 USA, [Johnson, K. A.] Harvard Med Sch, Boston, MA 02115 USA, [Mathias, S. R.] Harvard Med Sch, Boston, MA 02115 USA, [Rodrigue, A.] Harvard Med Sch, Boston, MA 02115 USA, [Schultz, A. P.] Harvard Med Sch, Boston, MA 02115 USA, [Sperling, R. A.] Harvard Med Sch, Boston, MA 02115 USA, [Grant, P. E.] Harvard Med Sch, Fetal Neonatal Neuroimaging & Dev Sci Ctr, Boston Childrens Hosp, Div Newborn Med & Neuroradiol, Boston, MA 02115 USA, [Groenewold, N. A.] Univ Cape Town, SA MRC Unit Child & Adolescent Hlth, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa, [Zar, H. J.] Univ Cape Town, SA MRC Unit Child & Adolescent Hlth, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa, [Gunning, F. M.] Weill Cornell Med, Dept Psychiat, Weill Cornell Inst Geriatr Psychiat, New York, NY USA, [Victoria, L. W.] Weill Cornell Med, Dept Psychiat, Weill Cornell Inst Geriatr Psychiat, New York, NY USA, [Hammill, C. F.] Mouse Imaging Ctr, Toronto, ON, Canada, [Hansson, O.] Lund Univ, Dept Clin Sci Malmo, Clin Memory Res Unit, Malmo, Sweden, [Hansson, O.] Skane Univ Hosp, Memory Clin, Malmo, Sweden, [Hedden, T.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA, [Hedden, T.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Athinoula Martinos Ctr Biomed Imaging, Boston, MA 02115 USA, [Heinz, A.] Charite Univ Med Berlin, Charite Campus Mitte, Berlin, Germany, [Heinz, A.] Free Univ Berlin, Charite Campus Mitte, Berlin, Germany, [Heinz, A.] Humboldt Univ, Dept Psychiat & Psychotherapy, Charite Campus Mitte, Berlin, Germany, [Heuer, K.] Max Planck Inst Human Cognit & Brain Sci, Dept Neuropsychol, Leipzig, Germany, [Heuer, K.] Univ Paris, Paris, France, [Toro, R.] Univ Paris, Paris, France, [Hoare, J.] Univ Cape Town, Dept Psychiat, Cape Town, South Africa, [Holla, B.] NIMHANS, Dept Integrat Med, Bengaluru, India, [Holla, B.] NIMHANS, Dept Psychiat, Accelerator Program Discovery Brain Disorders Usi, Bengaluru, India, [Holmes, A. J.] Yale Univ, Dept Psychol, New Haven, CT USA, [Villeneuve, S.] Yale Univ, Dept Psychol, New Haven, CT USA, [Holmes, A. J.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA, [Villeneuve, S.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA, [Huang, H.] Childrens Hosp Philadelphia, Radiol Res, Philadelphia, PA 19104 USA, [Ouyang, M.] Childrens Hosp Philadelphia, Radiol Res, Philadelphia, PA 19104 USA, [Huang, H.] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA, [Ipser, J.] Univ Cape Town, Dept Psychiat & Mental Hlth, Clin Neurosci Inst, Cape Town, South Africa, [Jack, C. R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA, [Jones, D. T.] Mayo Clin, Dept Radiol, Rochester, MN USA, Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil, [Jackowski, A. P.] Natl Inst Dev Psychiat, Beijing, Peoples R China, [Jia, T.] Fudan Univ, Inst Sci & Technol Brain Inspired Intelligence, Shanghai, Peoples R China, [Jia, T.] Fudan Univ, Minist Educ, Key Lab Computat Neurosci & Brain Inspired Intell, Shanghai, Peoples R China, [Jia, T.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Populat Neurosci & Precis Med PONS, SGDP Ctr, London, England, [Johnson, K. A.] Massachusetts Gen Hosp, Dept Neurol, Harvard Aging Brain Study, Boston, MA 02114 USA, [Schultz, A. P.] Massachusetts Gen Hosp, Dept Neurol, Harvard Aging Brain Study, Boston, MA 02114 USA, [Sperling, R. A.] Massachusetts Gen Hosp, Dept Neurol, Harvard Aging Brain Study, Boston, MA 02114 USA, [Johnson, K. A.] Brigham & Womens Hosp, Dept Neurol, Ctr Alzheimer Res & Treatment, 75 Francis St, Boston, MA 02115 USA, [Sperling, R. A.] Brigham & Womens Hosp, Dept Neurol, Ctr Alzheimer Res & Treatment, 75 Francis St, Boston, MA 02115 USA, [Johnson, K. A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA, [Jones, D. T.] Mayo Clin, Dept Neurol, Rochester, MN USA, [3R-BRAIN] Mayo Clin, Dept Neurol, Rochester, MN USA, [Kahn, R. S.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA, [Karlsson, H.] Univ Turku, Dept Psychiat, Dept Clin Med, Turku, Finland, [Karlsson, L.] Univ Turku, Dept Psychiat, Dept Clin Med, Turku, Finland, [Tuulari, J. J.] Univ Turku, Dept Psychiat, Dept Clin Med, Turku, Finland, [Karlsson, H.] Univ Turku, FinnBrain Birth Cohort Study, Turku Brain & Mind Ctr, Turku, Finland, [Karlsson, L.] Univ Turku, FinnBrain Birth Cohort Study, Turku Brain & Mind Ctr, Turku, Finland, [Tuulari, J. J.] Univ Turku, FinnBrain Birth Cohort Study, Turku Brain & Mind Ctr, Turku, Finland, [Karlsson, H.] Turku Univ Hosp, Turku, Finland, [Karlsson, L.] Turku Univ Hosp, Turku, Finland, [Tuulari, J. J.] Turku Univ Hosp, Turku, Finland, [Karlsson, H.] Turku Univ Hosp, Ctr Populat Hlth Res, Turku, Finland, [Karlsson, L.] Turku Univ Hosp, Ctr Populat Hlth Res, Turku, Finland, [Karlsson, H.] Univ Turku, Turku, Finland, [Karlsson, L.] Univ Turku, Turku, Finland, [Kawashima, R.] Tohoku Univ, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi, Japan, [Taki, Y.] Tohoku Univ, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi, Japan, [Thyreau, B.] Tohoku Univ, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi, Japan, [Kelley, E. A.] Queens Univ, Ctr Neurosci Studies, Dept Psychol, Kingston, ON, Canada, [Kelley, E. A.] Queens Univ, Ctr Neurosci Studies, Dept Psychiat, Kingston, ON, Canada, [Kern, S.] Univ Gothenburg, Neuropsychiat Epidemiol Unit, Dept Psychiat & Neurochem,Sahlgrenska Acad, Ctr Ageing & Hlth AGECAP,Inst Neurosci & Physiol, Gothenburg, Sweden, [Skoog, I.] Univ Gothenburg, Neuropsychiat Epidemiol Unit, Dept Psychiat & Neurochem,Sahlgrenska Acad, Ctr Ageing & Hlth AGECAP,Inst Neurosci & Physiol, Gothenburg, Sweden, [Zettergren, A.] Univ Gothenburg, Neuropsychiat Epidemiol Unit, Dept Psychiat & Neurochem,Sahlgrenska Acad, Ctr Ageing & Hlth AGECAP,Inst Neurosci & Physiol, Gothenburg, Sweden, [Kern, S.] Sahlgrens Univ Hosp, Psychiat Cognit & Old Age Psychiat Clin, Reg Vastra Gotaland, Gothenburg, Sweden, [Skoog, I.] Sahlgrens Univ Hosp, Psychiat Cognit & Old Age Psychiat Clin, Reg Vastra Gotaland, Gothenburg, Sweden, [Kim, K. W.] Seoul Natl Univ, Dept Brain & Cognit Sci, Coll Nat Sci, Seoul, South Korea, [Kim, K. W.] Seoul Natl Univ, Bundang Hosp, Dept Neuropsychiat, Seongnam, South Korea, [Kim, K. W.] Seoul Natl Univ, Dept Psychiat, Coll Med, Seoul, South Korea, [Kim, K. W.] SNU MRC, Inst Human Behav Med, Seoul, South Korea, [Lalonde, F.] NIMH, Sect Dev Neurogenom, Human Genet Branch, Bethesda, MD 20892 USA, [Raznahan, A.] NIMH, Sect Dev Neurogenom, Human Genet Branch, Bethesda, MD 20892 USA, [Lee, S.] Seoul Natl Univ, Coll Nat Sci, Dept Brain & Cognit Sci, Seoul, South Korea, [Lerch, J.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada, [Lerch, J.] Univ Oxford, Nuffield Dept Clin Neurosci, FMRIB, Wellcome Ctr Integrat Neuroimaging, Oxford, England, [Lewis, J. D.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada, [Li, J.] Univ Elect Sci & Technol China, Clin Hosp, Chengdu Brain Sci Inst, Chengdu, Peoples R China, [Liao, W.] Univ Elect Sci & Technol China, Clin Hosp, Chengdu Brain Sci Inst, Chengdu, Peoples R China, [Valdes-Sosa, P. A.] Univ Elect Sci & Technol China, Clin Hosp, Chengdu Brain Sci Inst, Chengdu, Peoples R China, [Liston, C.] Weill Cornell Med, Dept Psychiat, New York, NY USA, [Liston, C.] Weill Cornell Med, Brain & Mind Res Inst, New York, NY USA, [Lombardo, M. V.] Ist Italiano Tecnol, Ctr Neurosci & Cognit Syst UniTn, Lab Autism & Neurodev Disorders, Rovereto, Italy, [Lv, J.] Univ Sydney, Sch Biomed Engn, Sydney, NSW, Australia, [Lv, J.] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia, [Mallard, T. T.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA, [Marcelis, M.] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, EURON,Med Ctr, Maastricht, Netherlands, [Marcelis, M.] Inst Mental Hlth Care Eindhoven GGzE, Eindhoven, Netherlands, [Markello, R. D.] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ, Canada, [Misic, B.] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ, Canada, [Vasung, L.] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ, Canada, [Mazoyer, B.] Douglas Mental Hlth Univ Inst, Ludmer Ctr Neuroinformat & Mental Hlth, Montreal, PQ, Canada, [Meaney, M. J.] Douglas Mental Hlth Univ Inst, Ludmer Ctr Neuroinformat & Mental Hlth, Montreal, PQ, Canada, [Meaney, M. J.] Singapore Inst Clin Sci, Singapore, Singapore, [Mechelli, A.] Bordeaux Univ Hosp, Bordeaux, France, [Morgan, S. E.] Univ Cambridge, Dept Comp Sci & Technol, Cambridge, England, [Morgan, S. E.] Alan Turing Inst, London, England, [Vertes, P. E.] Alan Turing Inst, London, England, [Mothersill, D.] Natl Coll Ireland, Sch Business, Dept Psychol, Dublin, Ireland, [Mothersill, D.] Natl Univ Ireland Galway, Sch Psychol, Galway, Ireland, [Mothersill, D.] Natl Univ Ireland Galway, Ctr Neuroimaging & Cognit Genom, Galway, Ireland, [Mothersill, D.] Trinity Coll Dublin, Dept Psychiat, Dublin, Ireland, [Nigg, J.] Oregon Hlth & Sci Univ, Dept Psychiat, Sch Med, Portland, OR 97201 USA, [Ong, M. Q. W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Ctr Sleep & Cognit, Singapore, Singapore, [Qian, X.] Natl Univ Singapore, Yong Loo Lin Sch Med, Ctr Sleep & Cognit, Singapore, Singapore, [Zhou, J. H.] Natl Univ Singapore, Yong Loo Lin Sch Med, Ctr Sleep & Cognit, Singapore, Singapore, [Ortinau, C.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA, [Ossenkoppele, R.] Vrije Univ Amsterdam, Alzheimer Ctr Amsterdam, Amsterdam UMC, Dept Neurol,Amsterdam Neurosci, Amsterdam, Netherlands, [Ossenkoppele, R.] Lund Univ, Clin Memory Res Unit, Lund, Sweden, [Palaniyappan, L.] Univ Western Ontario, Robarts Res Inst, London, ON, Canada, [Palaniyappan, L.] Univ Western Ontario, Brain & Mind Inst, London, ON, Canada, [Pan, P. M.] Fed Univ Sao Poalo UNIFESP, Dept Psychiat, Sao Poalo, Brazil, [Pan, P. M.] Natl Inst Dev Psychiat Children & Adolescents INP, Sao Poalo, Brazil, [Zugman, A.] Natl Inst Dev Psychiat Children & Adolescents INP, Sao Poalo, Brazil, [Pantelis, C.] Univ Melbourne, Dept Psychiat, Melbourne Neuropsychiat Ctr, Carlton, Vic, Australia, [Pantelis, C.] Melbourne Hlth, Carlton, Vic, Australia, [Pantelis, C.] Univ Melbourne, Melbourne Sch Engn, Parkville, Vic, Australia, [Pantelis, C.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia, [Park, M. M.] Western Univ, Schulich Sch Med & Dent, Dept Psychiat, London, ON, Canada, [Rollins, C. K.] Univ Montreal, Dept Psychiat, Fac Med, Montreal, PQ, Canada, [Rollins, C. K.] Univ Montreal, CHU St Justine, Montreal, PQ, Canada, [Romero-Garcia, R.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada, [Romero-Garcia, R.] Univ Toronto, Dept Psychol, Toronto, ON, Canada, [Rosenberg, M. D.] Univ Toronto, Dept Physiol, Toronto, ON, Canada, [Rosenberg, M. D.] Univ Toronto, Dept Nutr Sci, Toronto, ON, Canada, [Paz-Linares, D.] Cuban Neurosci Ctr, Havana, Cuba, [Pichet Binette, A.] McGill Univ, Fac Med, Dept Psychiat, Montreal, PQ, Canada, [Villeneuve, S.] McGill Univ, Fac Med, Dept Psychiat, Montreal, PQ, Canada, [Pichet Binette, A.] Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada, [Villeneuve, S.] Douglas Mental Hlth Univ Inst, Montreal, PQ, Canada, [Qiu, J.] Southwest Univ, Sch Psychol, Chongqing, Peoples R China, [Qiu, A.] Natl Univ Singapore, N1 Inst Hlth, Dept Biomed Engn, Singapore, Singapore, [Rittman, T.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England, [Tsvetanov, K. A.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England, [Rollins, C. K.] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA, [Rollins, C. K.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA, [Romero-Garcia, R.] Univ Seville, Dpto Fisiol Med & Biofis, Inst Biomed Sevilla IBiS HUVR CSIC, Seville, Spain, [Rosenberg, M. D.] Univ Chicago, Dept Psychol, 5848 S Univ Ave, Chicago, IL 60637 USA, [Rosenberg, M. D.] Univ Chicago, Inst Neurosci, Chicago, IL USA, [Rowitch, D. H.] Univ Cambridge, Dept Paediat, Cambridge, England, [Rowitch, D. H.] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England, [Salum, G. A.] Univ Fed Rio Grande Sul UFRGS, Hosp Clin Porto Alegre, Dept Psychiat, Porto Alegre, RS, Brazil, [Salum, G. A.] Natl Inst Dev Psychiat INPD, Sao Paulo, Brazil, [Schaare, H. L.] Max Planck Inst Human Cognit & Brain Sci, Otto Hahn Grp Cognit Neurogenet, Leipzig, Germany, [Schaare, H. L.] Res Ctr Juelich, Inst Neurosci & Med INM 7 Brain & Behav, Julich, Germany, [Schultz, A. P.] Massachusetts Gen Hosp, Dept Radiol, Athinoula Martinos Ctr Biomed Imaging, Charlestown, MA USA, [Schumann, G.] Fudan Univ, Inst Sci & Technol Brain Inspired Intelligence, Ctr Populat Neurosci & Stratified Med PONS, Shanghai, Peoples R China, [Schumann, G.] Charite Campus Mitte, Dept Psychiat & Psychotherapy, Charite Mental Hlth, PONS Ctr, Berlin, Germany, [Scholl, M.] Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden, [Scholl, M.] Univ Gothenburg, Dept Psychiat & Neurochem, Gothenburg, Sweden, [Scholl, M.] UCL, Queens Sq Inst Neurol, Dementia Res Ctr, London, England, [Sharp, D.] UK Dementia Res Inst, Care Res & Technol Ctr, London, England, [Shinohara, R. T.] Univ Penn, Perelman Sch Med, Dept Radiol, Ctr Biomed Image Comp & Analyt, Philadelphia, PA 19104 USA, [Smyser, C. D.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA, [Smyser, C. D.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA, [Smyser, C. D.] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA, [Stein, D. J.] Univ Cape Town, Dept Psychiat, SA MRC Unit Risk & Resilience Mental Disorders, Cape Town, South Africa, [Stein, D. J.] Univ Cape Town, Neurosci Inst, Cape Town, South Africa, [Stolicyn, A.] Univ Edinburgh, Ctr Clin Brain Sci, Div Psychiat, Edinburgh, Midlothian, Scotland, [Whalley, H. C.] Univ Edinburgh, Ctr Clin Brain Sci, Div Psychiat, Edinburgh, Midlothian, Scotland, [Toro, R.] Inst Pasteur, Dept Neurosci, Paris, France, [Traut, N.] Inst Pasteur, Dept Neurosci, Paris, France, [Traut, N.] Univ Paris 05, Ctr Res & Interdisciplinar CRI, Paris, France, [Tsvetanov, K. A.] Univ Cambridge, Dept Psychol, Cambridge, England, [Turk-Browne, N. B.] Yale Univ, Wu Tsai Inst, New Haven, CT USA, [Tuulari, J. J.] Univ Turku, Dept Clin Med, Turku, Finland, [Tuulari, J. J.] Univ Turku, Turku Coll Sci Med & Technol, Turku, Finland, [Tzourio, C.] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, CHU Bordeaux, U1219,INSERM, Bordeaux, France, [Vachon-Presseau, E.] McGill Univ, Fac Dent Med & Oral Hlth Sci, Montreal, PQ, Canada, [Valdes-Sosa, P. A.] McGill Univ, Alan Edwards Ctr Res Pain AECRP, Montreal, PQ, Canada, [Valk, S. L.] Forschungszentrum Julich, Inst Neurosci & Med 7, Julich, Germany, [Valk, S. L.] Max Planck Inst Human Cognit & Brain Sci, Leipzig, Germany, [van Amelsvoort, T.] Maastricht Univ, Dept Psychiat & Neurosychol, Maastricht, Netherlands, [Vandekar, S. N.] Vanderbilt Univ, Dept Biostat, 221 Kirkland Hall, Nashville, TN 37235 USA, [Villeneuve, S.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA, [Villringer, A.] Univ Leipzig, Clin Cognit Neurol, Med Ctr, Leipzig, Germany, [Witte, A. V.] Univ Leipzig, Clin Cognit Neurol, Med Ctr, Leipzig, Germany, [Zuo, X. N.] Univ Leipzig, Clin Cognit Neurol, Med Ctr, Leipzig, Germany, [Wang, Y. S.] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing, Peoples R China, [Yang, N.] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing, Peoples R China, [Yeo, B.] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing, Peoples R China, [Zuo, X. N.] Beijing Normal Univ, State Key Lab Cognit Neurosci & Learning, Beijing, Peoples R China, [Wang, Y. S.] Beijing Normal Univ, IDG McGovern Inst Brain Res, Dev Populat Neuroscience Res Ctr, Beijing, Peoples R China, [Yang, N.] Beijing Normal Univ, IDG McGovern Inst Brain Res, Dev Populat Neuroscience Res Ctr, Beijing, Peoples R China, [Zuo, X. N.] Beijing Normal Univ, IDG McGovern Inst Brain Res, Dev Populat Neuroscience Res Ctr, Beijing, Peoples R China, [Wang, Y. S.] Natl Basic Sci Data Ctr, Beijing, Peoples R China, [Yang, N.] Natl Basic Sci Data Ctr, Beijing, Peoples R China, [Zuo, X. N.] Natl Basic Sci Data Ctr, Beijing, Peoples R China, [Wang, Y. S.] Chinese Acad Sci, Res Ctr Lifespan Dev Brain & Mind, Inst Psychol, Beijing, Peoples R China, [Yang, N.] Chinese Acad Sci, Res Ctr Lifespan Dev Brain & Mind, Inst Psychol, Beijing, Peoples R China, [Westman, E.] Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Clin Geriatr, Stockholm, Sweden, [Witte, A. V.] Univ Leipzig, CRC 1052 Obes Mech, Fac Med, Leipzig, Germany, [Zhou, J. H.] Natl Univ Singapore, Dept Elect & Comp Engn, Singapore, Singapore, [Yeo, B.] Natl Univ Singapore, Yong Loo Lin Sch Med, Ctr Sleep & Cognit, Singapore, Singapore, [Yeo, B.] Natl Univ Singapore, Yong Loo Lin Sch Med, Ctr Translat MR Res, Singapore, Singapore, [Yeo, B.] Natl Univ Singapore, N1 Inst Hlth, Singapore, Singapore, [Yeo, B.] Natl Univ Singapore, Inst Digital Med, Singapore, Singapore, [Yun, H.] Natl Univ Singapore, Integrat Sci & Engn Programme ISEP, Singapore, Singapore, [Zar, H. J.] Univ Melbourne, Dept Biomed Engn, Melbourne, Vic, Australia, [Zhou, J. H.] Natl Univ Singapore, Yong Loo Lin Sch Med, Ctr Translat Magnet Resonance Res, Singapore, Singapore, [Ziauddeen, H.] Univ Cambridge, Wellcome Trust MRC Inst Metab Sci, Cambridge, England, [Zugman, A.] NIMH, NIH, Bethesda, MD 20892 USA, [Zugman, A.] Escola Paulista Med, Dept Psychiat, Sao Paulo, Brazil, [Zuo, X. N.] Nanning Normal Univ, Sch Educ Sci, Key Lab Brain & Educ, Nanning, Peoples R China, British Academy Postdoctoral fellowship, NIMH, UKRI Medical Research Council, NIHR Cambridge Biomedical Research Centre, NIHR Senior Investigator award, MRC research infrastructure award, Commonwealth Scientific and Industrial Research Organisation (CSIRO), and Ontario Brain Institute

Subjects
631/378/2649, OpenPain Project, KNE96, Growth, Psychiatric-disorders, DISEASE, 3R-BRAIN, Brain charts, MRI Brain, OASIS-3, Disease, CCNP, 631/378/2571, UMN BCP, Multidisciplinary, medicine.diagnostic_test, PSYCHIATRIC-DISORDERS, article, Brain, Human brain, ASSOCIATION, Magnetic Resonance Imaging, Harvard Aging Brain Study, The Mayo Clinic Study of Aging, NSPN, medicine.anatomical_structure, GROWTH, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], ddc:500, BURDEN, WHITE-MATTER, FinnBrain, Harvard Aging Brain Study, Organization, Mri, MRI, medicine.medical_specialty, Concurrent validity, MODELS, Cam-CAN, Longevity, CALM Team, POND, Neuroimaging, Burden, ORGANIZATION, AIBL, The PREVENT-AD Research Group, VETSA, Cortical thickness, Association, Physical medicine and rehabilitation, FinnBrain, IMAGEN, KNE96, White-matter, medicine, Humans, ASRB, 631/378/1689, COBRE, business.industry, 631/378/2611, Brain morphometry, Neurosciences, Alzheimer’s Disease Repository Without Borders Investigators, Magnetic resonance imaging, Alzheimer’s Disease Neuroimaging Initiative, Anthropometry, Body Height, Brain growth, Birth, 59/57, Normative, IMAGEN, ENIGMA Developmental Brain Age working group, NSPN, business, CCNP, 3R-BRAIN, CORTICAL THICKNESS, Developing Human Connectome Project, ENIGMA Developmental Brain Age working group, The PREVENT-AD Research Group, VETSA, Bullmore, E.T
Abstract

Over the past few decades, neuroimaging has become a ubiquitous tool in basic research and clinical studies of the human brain. However, no reference standards currently exist to quantify individual differences in neuroimaging metrics over time, in contrast to growth charts for anthropometric traits such as height and weight1. Here we assemble an interactive open resource to benchmark brain morphology derived from any current or future sample of MRI data ( http://www.brainchart.io/ ). With the goal of basing these reference charts on the largest and most inclusive dataset available, acknowledging limitations due to known biases of MRI studies relative to the diversity of the global population, we aggregated 123,984 MRI scans, across more than 100 primary studies, from 101,457 human participants between 115 days post-conception to 100 years of age. MRI metrics were quantified by centile scores, relative to non-linear trajectories2 of brain structural changes, and rates of change, over the lifespan. Brain charts identified previously unreported neurodevelopmental milestones3, showed high stability of individuals across longitudinal assessments, and demonstrated robustness to technical and methodological differences between primary studies. Centile scores showed increased heritability compared with non-centiled MRI phenotypes, and provided a standardized measure of atypical brain structure that revealed patterns of neuroanatomical variation across neurological and psychiatric disorders. In summary, brain charts are an essential step towards robust quantification of individual variation benchmarked to normative trajectories in multiple, commonly used neuroimaging phenotypes., R.A.I.B. was supported by a British Academy Postdoctoral fellowship and by the Autism Research Trust. J. Seidlitz was supported by NIMH T32MH019112-29 and K08MH120564. S.R.W. was funded by UKRI Medical Research Council MC_UU_00002/2 and was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). E.T.B. was supported by an NIHR Senior Investigator award and the Wellcome Trust collaborative award for the Neuroscience in Psychiatry Network. A.F.A.-B. was supported by NIMH K08MH120564. Data were curated and analysed using a computational facility funded by an MRC research infrastructure award (MR/M009041/1) to the School of Clinical Medicine, University of Cambridge and supported by the mental health theme of the NIHR Cambridge Biomedical Research Centre.

Published
2022

22. Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study.

Author

Kerins, S, Nottage, J, Salazar de Pablo, G, Kempton, MJ, Tognin, S, Niemann, DH, de Haan, L, van Amelsvoort, T, Kwon, JS, Nelson, B, Mizrahi, R, McGuire, P, Fusar-Poli, P, PSYSCAN Consortium, Kerins, S, Nottage, J, Salazar de Pablo, G, Kempton, MJ, Tognin, S, Niemann, DH, de Haan, L, van Amelsvoort, T, Kwon, JS, Nelson, B, Mizrahi, R, McGuire, P, Fusar-Poli, P, and PSYSCAN Consortium

Abstract

BACKGROUND: The clinical high-risk for psychosis (CHR-P) paradigm was introduced to detect individuals at risk of developing psychosis and to establish preventive strategies. While current prediction of outcomes in the CHR-P state is based mostly on the clinical assessment of presenting features, several emerging biomarkers have been investigated in an attempt to stratify CHR-P individuals according to their individual trajectories and refine the diagnostic process. However, heterogeneity across subgroups is a key challenge that has limited the impact of the CHR-P prediction strategies, as the clinical validity of the current research is limited by a lack of external validation across sites and modalities. Despite these challenges, electroencephalography (EEG) biomarkers have been studied in this field and evidence suggests that EEG used in combination with clinical assessments may be a key measure for improving diagnostic and prognostic accuracy in the CHR-P state. The PSYSCAN EEG study is an international, multi-site, multimodal longitudinal project that aims to advance knowledge in this field. METHODS: Participants at 6 international sites take part in an EEG protocol including EEG recording, cognitive and clinical assessments. CHR-P participants will be followed up after 2 years and subcategorised depending on their illness progression regarding transition to psychosis. Differences will be sought between CHR-P individuals and healthy controls and between CHR-P individuals who transition and those who do not transition to psychosis using data driven computational analyses. DISCUSSION: This protocol addresses the challenges faced by previous studies of this kind to enable valid identification of predictive EEG biomarkers which will be combined with other biomarkers across sites to develop a prognostic tool in CHR-P. The PSYSCAN EEG study aims to pave the way for incorporating EEG biomarkers in the assessment of CHR-P individuals, to refine the diagnostic process a

Published
2022

23. Brain charts for the human lifespan

Author

Bethlehem, RAI, Seidlitz, J, White, SR, Vogel, JW, Anderson, KM, Adamson, C, Adler, S, Alexopoulos, GS, Anagnostou, E, Areces-Gonzalez, A, Astle, DE, Auyeung, B, Ayub, M, Bae, J, Ball, G, Baron-Cohen, S, Beare, R, Bedford, SA, Benegal, V, Beyer, F, Blangero, J, Blesa Cabez, M, Boardman, JP, Borzage, M, Bosch-Bayard, JF, Bourke, N, Calhoun, VD, Chakravarty, MM, Chen, C, Chertavian, C, Chetelat, G, Chong, YS, Cole, JH, Corvin, A, Costantino, M, Courchesne, E, Crivello, F, Cropley, VL, Crosbie, J, Crossley, N, Delarue, M, Delorme, R, Desrivieres, S, Devenyi, GA, Di Biase, MA, Dolan, R, Donald, KA, Donohoe, G, Dunlop, K, Edwards, AD, Elison, JT, Ellis, CT, Elman, JA, Eyler, L, Fair, DA, Feczko, E, Fletcher, PC, Fonagy, P, Franz, CE, Galan-Garcia, L, Gholipour, A, Giedd, J, Gilmore, JH, Glahn, DC, Goodyer, IM, Grant, PE, Groenewold, NA, Gunning, FM, Gur, RE, Gur, RC, Hammill, CF, Hansson, O, Hedden, T, Heinz, A, Henson, RN, Heuer, K, Hoare, J, Holla, B, Holmes, AJ, Holt, R, Huang, H, Im, K, Ipser, J, Jack, CR, Jackowski, AP, Jia, T, Johnson, KA, Jones, PB, Jones, DT, Kahn, RS, Karlsson, H, Karlsson, L, Kawashima, R, Kelley, EA, Kern, S, Kim, KW, Kitzbichler, MG, Kremen, WS, Lalonde, F, Landeau, B, Lee, S, Lerch, J, Lewis, JD, Li, J, Liao, W, Liston, C, Lombardo, MV, Lv, J, Lynch, C, Mallard, TT, Marcelis, M, Markello, RD, Mathias, SR, Mazoyer, B, McGuire, P, Meaney, MJ, Mechelli, A, Medic, N, Misic, B, Morgan, SE, Mothersill, D, Nigg, J, Ong, MQW, Ortinau, C, Ossenkoppele, R, Ouyang, M, Palaniyappan, L, Paly, L, Pan, PM, Pantelis, C, Park, MM, Paus, T, Pausova, Z, Paz-Linares, D, Pichet Binette, A, Pierce, K, Qian, X, Qiu, J, Qiu, A, Raznahan, A, Rittman, T, Rodrigue, A, Rollins, CK, Romero-Garcia, R, Ronan, L, Rosenberg, MD, Rowitch, DH, Salum, GA, Satterthwaite, TD, Schaare, HL, Schachar, RJ, Schultz, AP, Schumann, G, Scholl, M, Sharp, D, Shinohara, RT, Skoog, I, Smyser, CD, Sperling, RA, Stein, DJ, Stolicyn, A, Suckling, J, Sullivan, G, Taki, Y, Thyreau, B, Toro, R, Traut, N, Tsvetanov, KA, Turk-Browne, NB, Tuulari, JJ, Tzourio, C, Vachon-Presseau, E, Valdes-Sosa, MJ, Valdes-Sosa, PA, Valk, SL, van Amelsvoort, T, Vandekar, SN, Vasung, L, Victoria, LW, Villeneuve, S, Villringer, A, Vertes, PE, Wagstyl, K, Wang, YS, Warfield, SK, Warrier, V, Westman, E, Westwater, ML, Whalley, HC, Witte, AV, Yang, N, Yeo, B, Yun, H, Zalesky, A, Zar, HJ, Zettergren, A, Zhou, JH, Ziauddeen, H, Zugman, A, Zuo, XN, Bullmore, ET, Alexander-Bloch, AF, Bethlehem, RAI, Seidlitz, J, White, SR, Vogel, JW, Anderson, KM, Adamson, C, Adler, S, Alexopoulos, GS, Anagnostou, E, Areces-Gonzalez, A, Astle, DE, Auyeung, B, Ayub, M, Bae, J, Ball, G, Baron-Cohen, S, Beare, R, Bedford, SA, Benegal, V, Beyer, F, Blangero, J, Blesa Cabez, M, Boardman, JP, Borzage, M, Bosch-Bayard, JF, Bourke, N, Calhoun, VD, Chakravarty, MM, Chen, C, Chertavian, C, Chetelat, G, Chong, YS, Cole, JH, Corvin, A, Costantino, M, Courchesne, E, Crivello, F, Cropley, VL, Crosbie, J, Crossley, N, Delarue, M, Delorme, R, Desrivieres, S, Devenyi, GA, Di Biase, MA, Dolan, R, Donald, KA, Donohoe, G, Dunlop, K, Edwards, AD, Elison, JT, Ellis, CT, Elman, JA, Eyler, L, Fair, DA, Feczko, E, Fletcher, PC, Fonagy, P, Franz, CE, Galan-Garcia, L, Gholipour, A, Giedd, J, Gilmore, JH, Glahn, DC, Goodyer, IM, Grant, PE, Groenewold, NA, Gunning, FM, Gur, RE, Gur, RC, Hammill, CF, Hansson, O, Hedden, T, Heinz, A, Henson, RN, Heuer, K, Hoare, J, Holla, B, Holmes, AJ, Holt, R, Huang, H, Im, K, Ipser, J, Jack, CR, Jackowski, AP, Jia, T, Johnson, KA, Jones, PB, Jones, DT, Kahn, RS, Karlsson, H, Karlsson, L, Kawashima, R, Kelley, EA, Kern, S, Kim, KW, Kitzbichler, MG, Kremen, WS, Lalonde, F, Landeau, B, Lee, S, Lerch, J, Lewis, JD, Li, J, Liao, W, Liston, C, Lombardo, MV, Lv, J, Lynch, C, Mallard, TT, Marcelis, M, Markello, RD, Mathias, SR, Mazoyer, B, McGuire, P, Meaney, MJ, Mechelli, A, Medic, N, Misic, B, Morgan, SE, Mothersill, D, Nigg, J, Ong, MQW, Ortinau, C, Ossenkoppele, R, Ouyang, M, Palaniyappan, L, Paly, L, Pan, PM, Pantelis, C, Park, MM, Paus, T, Pausova, Z, Paz-Linares, D, Pichet Binette, A, Pierce, K, Qian, X, Qiu, J, Qiu, A, Raznahan, A, Rittman, T, Rodrigue, A, Rollins, CK, Romero-Garcia, R, Ronan, L, Rosenberg, MD, Rowitch, DH, Salum, GA, Satterthwaite, TD, Schaare, HL, Schachar, RJ, Schultz, AP, Schumann, G, Scholl, M, Sharp, D, Shinohara, RT, Skoog, I, Smyser, CD, Sperling, RA, Stein, DJ, Stolicyn, A, Suckling, J, Sullivan, G, Taki, Y, Thyreau, B, Toro, R, Traut, N, Tsvetanov, KA, Turk-Browne, NB, Tuulari, JJ, Tzourio, C, Vachon-Presseau, E, Valdes-Sosa, MJ, Valdes-Sosa, PA, Valk, SL, van Amelsvoort, T, Vandekar, SN, Vasung, L, Victoria, LW, Villeneuve, S, Villringer, A, Vertes, PE, Wagstyl, K, Wang, YS, Warfield, SK, Warrier, V, Westman, E, Westwater, ML, Whalley, HC, Witte, AV, Yang, N, Yeo, B, Yun, H, Zalesky, A, Zar, HJ, Zettergren, A, Zhou, JH, Ziauddeen, H, Zugman, A, Zuo, XN, Bullmore, ET, and Alexander-Bloch, AF

Abstract

Over the past few decades, neuroimaging has become a ubiquitous tool in basic research and clinical studies of the human brain. However, no reference standards currently exist to quantify individual differences in neuroimaging metrics over time, in contrast to growth charts for anthropometric traits such as height and weight1. Here we assemble an interactive open resource to benchmark brain morphology derived from any current or future sample of MRI data ( http://www.brainchart.io/ ). With the goal of basing these reference charts on the largest and most inclusive dataset available, acknowledging limitations due to known biases of MRI studies relative to the diversity of the global population, we aggregated 123,984 MRI scans, across more than 100 primary studies, from 101,457 human participants between 115 days post-conception to 100 years of age. MRI metrics were quantified by centile scores, relative to non-linear trajectories2 of brain structural changes, and rates of change, over the lifespan. Brain charts identified previously unreported neurodevelopmental milestones3, showed high stability of individuals across longitudinal assessments, and demonstrated robustness to technical and methodological differences between primary studies. Centile scores showed increased heritability compared with non-centiled MRI phenotypes, and provided a standardized measure of atypical brain structure that revealed patterns of neuroanatomical variation across neurological and psychiatric disorders. In summary, brain charts are an essential step towards robust quantification of individual variation benchmarked to normative trajectories in multiple, commonly used neuroimaging phenotypes.

Published
2022

24. Publisher Correction: Brain charts for the human lifespan.

Author

Bethlehem, RAI, Seidlitz, J, White, SR, Vogel, JW, Anderson, KM, Adamson, C, Adler, S, Alexopoulos, GS, Anagnostou, E, Areces-Gonzalez, A, Astle, DE, Auyeung, B, Ayub, M, Bae, J, Ball, G, Baron-Cohen, S, Beare, R, Bedford, SA, Benegal, V, Beyer, F, Blangero, J, Blesa Cábez, M, Boardman, JP, Borzage, M, Bosch-Bayard, JF, Bourke, N, Calhoun, VD, Chakravarty, MM, Chen, C, Chertavian, C, Chetelat, G, Chong, YS, Cole, JH, Corvin, A, Costantino, M, Courchesne, E, Crivello, F, Cropley, VL, Crosbie, J, Crossley, N, Delarue, M, Delorme, R, Desrivieres, S, Devenyi, GA, Di Biase, MA, Dolan, R, Donald, KA, Donohoe, G, Dunlop, K, Edwards, AD, Elison, JT, Ellis, CT, Elman, JA, Eyler, L, Fair, DA, Feczko, E, Fletcher, PC, Fonagy, P, Franz, CE, Galan-Garcia, L, Gholipour, A, Giedd, J, Gilmore, JH, Glahn, DC, Goodyer, IM, Grant, PE, Groenewold, NA, Gunning, FM, Gur, RE, Gur, RC, Hammill, CF, Hansson, O, Hedden, T, Heinz, A, Henson, RN, Heuer, K, Hoare, J, Holla, B, Holmes, AJ, Holt, R, Huang, H, Im, K, Ipser, J, Jack, CR, Jackowski, AP, Jia, T, Johnson, KA, Jones, PB, Jones, DT, Kahn, RS, Karlsson, H, Karlsson, L, Kawashima, R, Kelley, EA, Kern, S, Kim, KW, Kitzbichler, MG, Kremen, WS, Lalonde, F, Landeau, B, Lee, S, Lerch, J, Lewis, JD, Li, J, Liao, W, Liston, C, Lombardo, MV, Lv, J, Lynch, C, Mallard, TT, Marcelis, M, Markello, RD, Mathias, SR, Mazoyer, B, McGuire, P, Meaney, MJ, Mechelli, A, Medic, N, Misic, B, Morgan, SE, Mothersill, D, Nigg, J, Ong, MQW, Ortinau, C, Ossenkoppele, R, Ouyang, M, Palaniyappan, L, Paly, L, Pan, PM, Pantelis, C, Park, MM, Paus, T, Pausova, Z, Paz-Linares, D, Pichet Binette, A, Pierce, K, Qian, X, Qiu, J, Qiu, A, Raznahan, A, Rittman, T, Rodrigue, A, Rollins, CK, Romero-Garcia, R, Ronan, L, Rosenberg, MD, Rowitch, DH, Salum, GA, Satterthwaite, TD, Schaare, HL, Schachar, RJ, Schultz, AP, Schumann, G, Schöll, M, Sharp, D, Shinohara, RT, Skoog, I, Smyser, CD, Sperling, RA, Stein, DJ, Stolicyn, A, Suckling, J, Sullivan, G, Taki, Y, Thyreau, B, Toro, R, Traut, N, Tsvetanov, KA, Turk-Browne, NB, Tuulari, JJ, Tzourio, C, Vachon-Presseau, É, Valdes-Sosa, MJ, Valdes-Sosa, PA, Valk, SL, van Amelsvoort, T, Vandekar, SN, Vasung, L, Victoria, LW, Villeneuve, S, Villringer, A, Vértes, PE, Wagstyl, K, Wang, YS, Warfield, SK, Warrier, V, Westman, E, Westwater, ML, Whalley, HC, Witte, AV, Yang, N, Yeo, B, Yun, H, Zalesky, A, Zar, HJ, Zettergren, A, Zhou, JH, Ziauddeen, H, Zugman, A, Zuo, XN, 3R-BRAIN, AIBL, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Repository Without Borders Investigators, CALM Team, Cam-CAN, CCNP, COBRE, cVEDA, ENIGMA Developmental Brain Age Working Group, Developing Human Connectome Project, FinnBrain, Harvard Aging Brain Study, IMAGEN, KNE96, Mayo Clinic Study of Aging, NSPN, POND, PREVENT-AD Research Group, VETSA, Bullmore, ET, Alexander-Bloch, AF, Bethlehem, RAI, Seidlitz, J, White, SR, Vogel, JW, Anderson, KM, Adamson, C, Adler, S, Alexopoulos, GS, Anagnostou, E, Areces-Gonzalez, A, Astle, DE, Auyeung, B, Ayub, M, Bae, J, Ball, G, Baron-Cohen, S, Beare, R, Bedford, SA, Benegal, V, Beyer, F, Blangero, J, Blesa Cábez, M, Boardman, JP, Borzage, M, Bosch-Bayard, JF, Bourke, N, Calhoun, VD, Chakravarty, MM, Chen, C, Chertavian, C, Chetelat, G, Chong, YS, Cole, JH, Corvin, A, Costantino, M, Courchesne, E, Crivello, F, Cropley, VL, Crosbie, J, Crossley, N, Delarue, M, Delorme, R, Desrivieres, S, Devenyi, GA, Di Biase, MA, Dolan, R, Donald, KA, Donohoe, G, Dunlop, K, Edwards, AD, Elison, JT, Ellis, CT, Elman, JA, Eyler, L, Fair, DA, Feczko, E, Fletcher, PC, Fonagy, P, Franz, CE, Galan-Garcia, L, Gholipour, A, Giedd, J, Gilmore, JH, Glahn, DC, Goodyer, IM, Grant, PE, Groenewold, NA, Gunning, FM, Gur, RE, Gur, RC, Hammill, CF, Hansson, O, Hedden, T, Heinz, A, Henson, RN, Heuer, K, Hoare, J, Holla, B, Holmes, AJ, Holt, R, Huang, H, Im, K, Ipser, J, Jack, CR, Jackowski, AP, Jia, T, Johnson, KA, Jones, PB, Jones, DT, Kahn, RS, Karlsson, H, Karlsson, L, Kawashima, R, Kelley, EA, Kern, S, Kim, KW, Kitzbichler, MG, Kremen, WS, Lalonde, F, Landeau, B, Lee, S, Lerch, J, Lewis, JD, Li, J, Liao, W, Liston, C, Lombardo, MV, Lv, J, Lynch, C, Mallard, TT, Marcelis, M, Markello, RD, Mathias, SR, Mazoyer, B, McGuire, P, Meaney, MJ, Mechelli, A, Medic, N, Misic, B, Morgan, SE, Mothersill, D, Nigg, J, Ong, MQW, Ortinau, C, Ossenkoppele, R, Ouyang, M, Palaniyappan, L, Paly, L, Pan, PM, Pantelis, C, Park, MM, Paus, T, Pausova, Z, Paz-Linares, D, Pichet Binette, A, Pierce, K, Qian, X, Qiu, J, Qiu, A, Raznahan, A, Rittman, T, Rodrigue, A, Rollins, CK, Romero-Garcia, R, Ronan, L, Rosenberg, MD, Rowitch, DH, Salum, GA, Satterthwaite, TD, Schaare, HL, Schachar, RJ, Schultz, AP, Schumann, G, Schöll, M, Sharp, D, Shinohara, RT, Skoog, I, Smyser, CD, Sperling, RA, Stein, DJ, Stolicyn, A, Suckling, J, Sullivan, G, Taki, Y, Thyreau, B, Toro, R, Traut, N, Tsvetanov, KA, Turk-Browne, NB, Tuulari, JJ, Tzourio, C, Vachon-Presseau, É, Valdes-Sosa, MJ, Valdes-Sosa, PA, Valk, SL, van Amelsvoort, T, Vandekar, SN, Vasung, L, Victoria, LW, Villeneuve, S, Villringer, A, Vértes, PE, Wagstyl, K, Wang, YS, Warfield, SK, Warrier, V, Westman, E, Westwater, ML, Whalley, HC, Witte, AV, Yang, N, Yeo, B, Yun, H, Zalesky, A, Zar, HJ, Zettergren, A, Zhou, JH, Ziauddeen, H, Zugman, A, Zuo, XN, 3R-BRAIN, AIBL, Alzheimer’s Disease Neuroimaging Initiative, Alzheimer’s Disease Repository Without Borders Investigators, CALM Team, Cam-CAN, CCNP, COBRE, cVEDA, ENIGMA Developmental Brain Age Working Group, Developing Human Connectome Project, FinnBrain, Harvard Aging Brain Study, IMAGEN, KNE96, Mayo Clinic Study of Aging, NSPN, POND, PREVENT-AD Research Group, VETSA, Bullmore, ET, and Alexander-Bloch, AF

Published
2022

25. Usability, Feasibility, and Effect of a Biocueing Intervention in Addition to a Moderated Digital Social Therapy-Platform in Young People With Emerging Mental Health Problems: A Mixed-Method Approach.

Author

van Doorn, M, Nijhuis, LA, Monsanto, A, van Amelsvoort, T, Popma, A, Jaspers, MWM, Noordzij, ML, Öry, FG, Alvarez-Jimenez, M, Nieman, DH, van Doorn, M, Nijhuis, LA, Monsanto, A, van Amelsvoort, T, Popma, A, Jaspers, MWM, Noordzij, ML, Öry, FG, Alvarez-Jimenez, M, and Nieman, DH

Abstract

INTRODUCTION: To optimize treatment, it is of utmost importance to take into account the myriad of biological, social, and psychological changes that young people go through during adolescence which make them more vulnerable for developing mental health problems. Biocueing, a non-invasive method to transform physiological parameters into an observable signal, could strengthen stress- and emotion regulation by cueing physiologically unusual values in daily life. The aim of this study is to investigate the usability, feasibility, and exploratory effect of biocueing in addition to ENgage YOung people earlY (ENYOY), a moderated digital social therapy-platform, in young people with emerging mental health complaints. METHODS: A user-centered mixed-method design was used. A focus group was conducted to optimize the ENYOY-platform and biocueing intervention. Biocueing was operationalized by a smartwatch and the Sense-IT app. A within-subjects design was used; 10 days for all participants 'biofeedback off' (control), followed by 10 days 'biofeedback on' (experimental). Emotional awareness and perceived stress were measured using ecological momentary assessment. Eight individuals participated. User-friendliness, usability, and acceptance were assessed using a qualitative design. RESULTS: Findings from the focus group resulted in several adaptations of the biocueing intervention to the ENYOY-platform and vice versa. The average measurement compliance rate was 78.8%. Level-one findings showed different individual effects on perceived stress and emotional awareness. Level-two analyses showed no overall effects on perceived stress (B = -0.020, p = 0.562) and overall positive effects on emotional awareness (B = 0.030, p = 0.048) with small effect sizes (Improvement Rate Difference = 0.05-0.35). The intervention was found to be acceptable and showed moderate usability. Participants indicated they experienced improvements in reflection on feelings and changes in behavior, such as pa

Published
2022

26. Moderated digital social therapy for young people with emerging mental health problems: A user-centered mixed-method design and usability study.

Author

van Doorn, M, Monsanto, A, Boeschoten, CM, van Amelsvoort, T, Popma, A, Öry, FG, Alvarez-Jimenez, M, Gleeson, J, Jaspers, MWM, Nieman, DH, van Doorn, M, Monsanto, A, Boeschoten, CM, van Amelsvoort, T, Popma, A, Öry, FG, Alvarez-Jimenez, M, Gleeson, J, Jaspers, MWM, and Nieman, DH

Abstract

INTRODUCTION: Over 25% of Dutch young people are psychologically unhealthy. Individual and societal consequences that follow from having mental health complaints at this age are substantial. Young people need care which is often unavailable. ENgage YOung people earlY (ENYOY) is a moderated digital social therapy-platform that aims to help youngsters with emerging mental health complaints. Comprehensive research is being conducted into the effects and to optimize and implement the ENYOY-platform throughout the Netherlands. The aim of this study is to explore the usability and user experience of the ENYOY-platform. METHODS: A user-centered mixed-method design was chosen. 26 young people aged 16-25 with emerging mental health complaints participated. Semi-structured interviews were conducted to explore usability, user-friendliness, impact, accessibility, inclusivity, and connection (Phase 1). Phase 2 assessed usability problems using the concurrent and retrospective Think Aloud-method. User experience and perceived helpfulness were assessed using a 10-point rating scale and semi-structured interviews (Phase 3). The Health Information Technology Usability Evaluation Scale (Health-ITUES; Phase 1) and System Usability Scale (SUS; Phase 2 and 3) were administered. Qualitative data was analyzed using thematic analysis. Task completion rate and time were tracked and usability problems were categorized using the Nielsen's rating scale (Phase 2). RESULTS: Adequate to high usability was found (Phase 1 Health-ITUES 4.0(0.34); Phase 2 SUS 69,5(13,70); Phase 3 SUS 71,6(5,63)). Findings from Phase 1 (N = 10) indicated that users viewed ENYOY as a user-friendly, safe, accessible, and inclusive initiative which helped them reduce their mental health complaints and improve quality of life. Phase 2 (N = 10) uncovered 18 usability problems of which 5 of major severity (e.g. troubles accessing the platform). Findings from Phase 3 (N = 6) suggested that users perceived the coaching calls

Published
2022

27. Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study

Author

Burin, L.M., Hahn, M.K., da Rocha, N.S., van Amelsvoort, T., Bartels-Velthuis, A.A., Bruggeman, R., de Haan, L., Schirmbeck, F., Simons, C.J.P., van Os, J., Cahn, W., Burin, L.M., Hahn, M.K., da Rocha, N.S., van Amelsvoort, T., Bartels-Velthuis, A.A., Bruggeman, R., de Haan, L., Schirmbeck, F., Simons, C.J.P., van Os, J., and Cahn, W.

Abstract

Introduction: Antipsychotics (APs) can cause weight gain. Little is known about changes in weight when APs are combined with other psychotropics. This study examines the weight change in patients undergoing long-term treatment with APs or with AP combined with other psychotropics. Methods: Patients with non-affective psychotic disorder from the GROUP study were divided into three groups: AP medication group (APm) (n = 100), AP in combination with other psychotropics (APc) (n = 73), and medication-free (Meds-free) (n = 100). Weight change was examined at inclusion and after three years using a paired-sample t-test. An Independent-sample t-test was performed to evaluate weight change among patients taking clozapine, olanzapine, and quetiapine and individuals not taking these medications. Linear regression was performed to evaluate the association between covariates and weight. Results: Patients in the APm group [mean = 1.800 kg, t(99)=2.849, 95% CI(0.546, 3.054), p = 0.005] and the APc group [mean = 1.877 kg, t(72)=2.688, 95% CI(0.485, 3.268), p = 0.009] showed significant weight gain. Patients taking clozapine, olanzapine or quetiapine showed significant weight gain compared to those not taking these medications [mean difference=1.707 kg, t(271)= 2.061, 95% CI(0.077, 3.337), p = 0.040)]. Conclusion: Patients receiving APs and APs with other psychotropics gain weight during long-term treatment. It is possible that weight gain is mainly driven by APs.

Published
2022

31. Correction to: Efficacy of Acceptance and Commitment Therapy in Daily Life (ACT-DL) in early psychosis: study protocol for a multi-centre randomized controlled trial (Trials, (2019), 20, 1, (769), 10.1186/s13063-019-3912-4)

Author

Reininghaus, U., Klippel, A., Steinhart, H., Vaessen, T., van Nierop, M., Viechtbauer, W., Batink, T., Kasanova, Z., van Aubel, E., van Winkel, R., Marcelis, M., van Amelsvoort, T., van der Gaag, M., de Haan, L., Myin-Germeys, I., Adult Psychiatry, APH - Mental Health, Amsterdam Neuroscience - Complex Trait Genetics, and Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep

Subjects
SDG 10 - Reduced Inequalities
Abstract

© 2021, The Author(s).Following the publication of the original article [1], the authors discovered a typographical error in the method section under the inclusion criteria subsection. The text “[the] inclusion criteria are as follows: (1) aged 16-65 years” should read “[the] inclusion criteria are as follows: (1) aged 15-65 years”. The authors were granted ethical approval for this age range by the MERC at Maastricht University Medical Centre (MUMC), The Netherlands reference: (NL46439.068.13) and the University Clinical Leuven, Belgium (reference: B322201629214). The typographical error therefore has had no implications for the RCT.

Published
2021

32. Burden of mental health problems: quality of life and cost-of-illness in youth consulting Dutch walk-in youth health centres.

Author

Leijdesdorff, S. M. J., Huijs, C. E. M., Klaassen, R. M. C., Popma, A., van Amelsvoort, T. A. M. J., and Evers, S. M. A. A.

Subjects
MENTAL illness, ECONOMICS, PSYCHIATRIC epidemiology, MEDICAL care costs, MENTAL health, MEDICAL care use, COMPARATIVE studies, SEX distribution, CHILD psychopathology, QUALITY of life, QUESTIONNAIRES, PSYCHIATRIC treatment, ADULTS, ADOLESCENCE
Abstract

Little is known about the burden of (sub-threshold) mental health problems in youth. To examine the burden of mental health problems in terms of health-related quality of life (HRQoL) and cost-of-illness, for first visitors of the Dutch youth walk-in centres (@ease). A bottom-up, prevalence-based burden of disease study from a societal perspective. HRQoL was assessed through the EuroQoL (EQ-5D-5L), and cost-of-illness via items about truancy and health care utilization. Participants (N = 80) showed a decreased HRQoL compared to the general population of Dutch youth. In the three months prior to their 1st attendance, participants skipped on average 4.11 days of school and had 1.03 health care visits, leading to total costs of €512.64 per person. Females had significantly higher health care costs and lower HRQoL. Health care use was lower in those not speaking the Dutch language. Living alone was a significant predictor of truancy (costs), and therefore total costs. Mental health problems in youth consulting @ease have a considerable impact on the individual's HRQoL, and an economic impact on society, yet almost 75% is not receiving care. A lack of interventions in this critical period in life may have major lifelong consequences. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Efficacy of Acceptance and Commitment Therapy in Daily Life (ACT-DL) in early psychosis: Results from the multi-center INTERACT randomized controlled trial

Author

van Aubel E, Frederike Schirmbeck, de Haan L, van Winkel R, Klippel A, van Amelsvoort T, Wolfgang Viechtbauer, Ulrich Reininghaus, Lafit G, Thomas Vaessen, Inez Myin-Germeys, Batink T, van der Gaag M, Machteld Marcelis, and Steinhart H

Subjects
Psychosis, medicine.medical_specialty, Experience sampling method, business.industry, medicine.disease, Affect (psychology), Acceptance and commitment therapy, Mental health, law.invention, Distress, Randomized controlled trial, law, medicine, business, Psychiatry, Adverse effect
Abstract

ImportanceTreatment in the early stages of psychosis is crucial to prevent poor clinical and social outcomes. Currently, no preventive interventions are available that reduce psychotic distress, or affective and negative symptoms as well as functioning, calling for more and dedicated treatments for these.ObjectiveTo investigate the efficacy of Acceptance and Commitment Therapy in Daily Life (ACT-DL), combining face-to-face therapy with an Ecological Momentary Intervention (EMI), in addition to treatment as usual for psychotic distress, in comparison to treatment as usual only.DesignThis single-blinded randomized clinical INTERACT trial investigated participants post-intervention and at 6 and 12-month follow-up. Participants were recruited between June 1, 2015 and December 31, 2018. Assessors were blinded to treatment allocation.SettingINTERACT is a multi-center trial recruiting participants from secondary mental health services in 5 regions in Belgium and The Netherlands.ParticipantsThe sample was a referral sample of individuals aged 15-65 years with a clinically established UHR or FEP status.InterventionsIndividuals were randomly assigned (1:1) to ACT-DL, consisting of 8 ACT sessions augmented with an EMI app in addition to treatment as usual, or to treatment as usual only.Main outcomes and measuresThe primary outcome was a reduction in psychotic distress as assessed with CAARMS at post-intervention, 6-and 12-month follow-up. Secondary outcomes included symptom severity (measured with BPRS and BNNS), functioning (measured with SOFAS and SFS) and momentary psychotic distress (measured with the Experience Sampling Method, a structured diary technique). All analyses were described in the trial protocol and in a postregistration on the open-science framework, prior to accessing the data.ResultsOf the 196 individuals assessed for eligibility, 148 were randomized to ACT-DL+TAU (n=71) or TAU (n=77) (72 female (49%), average age 25 (SD = 6), 71 FEP (48%)). 115 (78%) provided primary outcome data at least at one follow-up assessment. There was no evidence of a greater reduction in CAARMS distress in ACT-DL+TAU compared to TAU (χ2(3)=2.38; p=.50). However, general psychopathology (χ2(3)=14.44; p=.002); affective (χ2(3)=8.55; p=.04) and negative symptom severity (χ2(3)=19.96; p2(3)=15.96; p=.001) in. Furthermore, global functioning improved (χ2(3)=8.72; p=.033) in ACT-DL+TAU compared to TAU, whereas social functioning failed to reach significance (χ2(3)=7.41; p=.060). Finally, a clear and significant reduction was found in momentary psychotic distress (χ2(3)=21.56; p2(3)=1.02; p=.599), momentary positive (χ2(3)=4.17; p=.124) or negative (χ2(3)=2.78; p=.249) affect. No serious adverse events directly related to the therapy occurred.Conclusions and relevanceINTERACT did not support a significant effect on psychotic distress as assessed with the CAARMS. However, significant improvements were found for momentary psychotic distress, global functioning and negative symptomatology. These results are promising given that these latter problems are among the hardest to treat.Trial RegistrationDutch Trial Register: NTR4252Key PointsQuestionCan Acceptance and Commitment Therapy (ACT) in Daily Life, a combined face-to-face ACT intervention with a digital daily life Ecological Momentary Intervention, reduce psychotic distress in the early stages of psychosis?FindingsThis randomized clinical trial of 148 individuals in the early stages of psychosis (UHR or FEP) found no evidence that ACT-DL improved psychotic distress at post-intervention, 6 or 12-month follow-up over and above treatment as usual. However, significant effects were found for momentary psychotic distress, negative symptoms and functioning.MeaningWhereas the blended care approach of face-to-face ACT with the ACT-DL EMI did not improve psychotic distress over and above treatment as usual, it provided a promising avenue for the treatment of momentary psychotic distress as well as for negative symptoms and improving functioning, some of the hardest to treat problems in individuals with UHR and FEP.

Published
2021

34. Correction: Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study (Molecular Psychiatry, (2021), 10.1038/s41380-021-01108-y)

Author

Rogdaki, M., Devroye, C., Ciampoli, M., Veronese, M., Ashok, A. H., Mccutcheon, R. A., Jauhar, S., Bonoldi, I., Gudbrandsen, M., Daly, E., van Amelsvoort, T., Van Den Bree, M., Owen, M. J., Turkheimer, F., Papaleo, F., and Howes, O. D.

Published
2021

35. Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings

Author

Velthorst, E, Mollon, J, Murray, RM, de Haan, L, Germeys, IM, Glahn, DC, Arango, C, van der Ven, E, Di Forti, M, Bernardo, M, Guloksuz, S, Delespaul, P, Mezquida, G, Amoretti, S, Bobes, J, Saiz, PA, Garcia-Portilla, MP, Santos, JL, Jimenez-Lopez, E, Sanjuan, J, Aguilar, EJ, Arrojo, M, Carracedo, A, Lopez, G, Gonzalez-Penas, J, Parellada, M, Atbasoglu, C, Saka, MC, Ucok, A, Alptekin, K, Akdede, B, Binbay, T, Altinyazar, V, Ulas, H, Yalincetin, B, Gumus-Akay, G, Beyaz, BC, Soygur, H, Cankurtaran, ES, Kaymak, SU, Maric, NP, Mihaljevic, MM, Petrovic, SA, Mirjanic, T, Del-Ben, CM, Ferraro, L, Gayer-Anderson, C, Jones, PB, Jongsma, HE, Kirkbride, JB, La Cascia, C, Lasalvia, A, Tosato, S, Llorca, P-M, Menezes, PR, Morgan, C, Quattrone, D, Menchetti, M, Selten, J-P, Szoke, A, Tarricone, I, Tortelli, A, McGuire, P, Valmaggia, L, Kempton, MJ, van der Gaag, M, Riecher-Rossler, A, Bressan, RA, Barrantes-Vidal, N, Nelson, B, McGorry, P, Pantelis, C, Krebs, M-O, Ruhrmann, S, Sachs, G, Rutten, BPF, van Os, J, Alizadeh, BZ, van Amelsvoort, T, Bartels-Velthuis, AA, Bruggeman, R, van Beveren, NJ, Luykx, JJ, Cahn, W, Simons, CJP, Kahn, RS, Schirmbeck, F, van Winkel, R, Reichenberg, A, Velthorst, E, Mollon, J, Murray, RM, de Haan, L, Germeys, IM, Glahn, DC, Arango, C, van der Ven, E, Di Forti, M, Bernardo, M, Guloksuz, S, Delespaul, P, Mezquida, G, Amoretti, S, Bobes, J, Saiz, PA, Garcia-Portilla, MP, Santos, JL, Jimenez-Lopez, E, Sanjuan, J, Aguilar, EJ, Arrojo, M, Carracedo, A, Lopez, G, Gonzalez-Penas, J, Parellada, M, Atbasoglu, C, Saka, MC, Ucok, A, Alptekin, K, Akdede, B, Binbay, T, Altinyazar, V, Ulas, H, Yalincetin, B, Gumus-Akay, G, Beyaz, BC, Soygur, H, Cankurtaran, ES, Kaymak, SU, Maric, NP, Mihaljevic, MM, Petrovic, SA, Mirjanic, T, Del-Ben, CM, Ferraro, L, Gayer-Anderson, C, Jones, PB, Jongsma, HE, Kirkbride, JB, La Cascia, C, Lasalvia, A, Tosato, S, Llorca, P-M, Menezes, PR, Morgan, C, Quattrone, D, Menchetti, M, Selten, J-P, Szoke, A, Tarricone, I, Tortelli, A, McGuire, P, Valmaggia, L, Kempton, MJ, van der Gaag, M, Riecher-Rossler, A, Bressan, RA, Barrantes-Vidal, N, Nelson, B, McGorry, P, Pantelis, C, Krebs, M-O, Ruhrmann, S, Sachs, G, Rutten, BPF, van Os, J, Alizadeh, BZ, van Amelsvoort, T, Bartels-Velthuis, AA, Bruggeman, R, van Beveren, NJ, Luykx, JJ, Cahn, W, Simons, CJP, Kahn, RS, Schirmbeck, F, van Winkel, R, and Reichenberg, A

Abstract

Important questions remain about the profile of cognitive impairment in psychotic disorders across adulthood and illness stages. The age-associated profile of familial impairments also remains unclear, as well as the effect of factors, such as symptoms, functioning, and medication. Using cross-sectional data from the EU-GEI and GROUP studies, comprising 8455 participants aged 18 to 65, we examined cognitive functioning across adulthood in patients with psychotic disorders (n = 2883), and their unaffected siblings (n = 2271), compared to controls (n = 3301). An abbreviated WAIS-III measured verbal knowledge, working memory, visuospatial processing, processing speed, and IQ. Patients showed medium to large deficits across all functions (ES range = -0.45 to -0.73, p < 0.001), while siblings showed small deficits on IQ, verbal knowledge, and working memory (ES = -0.14 to -0.33, p < 0.001). Magnitude of impairment was not associated with participant age, such that the size of impairment in older and younger patients did not significantly differ. However, first-episode patients performed worse than prodromal patients (ES range = -0.88 to -0.60, p < 0.001). Adjusting for cannabis use, symptom severity, and global functioning attenuated impairments in siblings, while deficits in patients remained statistically significant, albeit reduced by half (ES range = -0.13 to -0.38, p < 0.01). Antipsychotic medication also accounted for around half of the impairment in patients (ES range = -0.21 to -0.43, p < 0.01). Deficits in verbal knowledge, and working memory may specifically index familial, i.e., shared genetic and/or shared environmental, liability for psychotic disorders. Nevertheless, potentially modifiable illness-related factors account for a significant portion of the cognitive impairment in psychotic disorders.

Published
2021

36. Primary prevention of depression: An umbrella review of controlled interventions.

Author

Salazar de Pablo, G, Solmi, M, Vaquerizo-Serrano, J, Radua, J, Passina, A, Mosillo, P, Correll, CU, Borgwardt, S, Galderisi, S, Bechdolf, A, Pfennig, A, Bauer, M, Kessing, LV, van Amelsvoort, T, Nieman, DH, Domschke, K, Krebs, M-O, Sand, M, Vieta, E, McGuire, P, Arango, C, Shin, JI, Fusar-Poli, P, Salazar de Pablo, G, Solmi, M, Vaquerizo-Serrano, J, Radua, J, Passina, A, Mosillo, P, Correll, CU, Borgwardt, S, Galderisi, S, Bechdolf, A, Pfennig, A, Bauer, M, Kessing, LV, van Amelsvoort, T, Nieman, DH, Domschke, K, Krebs, M-O, Sand, M, Vieta, E, McGuire, P, Arango, C, Shin, JI, and Fusar-Poli, P

Abstract

BACKGROUND: Primary prevention has the potential to modify the course of depression, but the consistency and magnitude of this effect are currently undetermined. METHODS: PRISMA and RIGHT compliant (PROSPERO:CRD42020179659) systematic meta-review, PubMed/Web of Science, up to June 2020. Meta-analyses of controlled interventions for the primary prevention of depressive symptoms [effect measures: standardized mean difference (SMD)] or depressive disorders [effect measure: relative risk (RR)] were carried out. Results were stratified by: (i) age range; (ii) target population (general and/or at-risk); (iii) intervention type. Quality (assessed with AMSTAR/AMSTAR-PLUS content) and credibility (graded as high/moderate/low) were assessed. USPSTF grading system was used for recommendations. RESULTS: Forty-six meta-analyses (k=928 individual studies, n=286,429 individuals, mean age=22.4 years, 81.1% female) were included. Effect sizes were: SMD=0.08-0.53; for depressive symptoms; RR=0.90-0.28 for depressive disorders. Sensitivity analyses including only RCTs did not impact the findings. AMSTAR median=9 (IQR=8-9); AMSTAR-PLUS content median=4.25 (IQR=4-5). Credibility of the evidence was insufficient/low in 43 (93.5%) meta-analyses, moderate in two (4.3%), and high in one (2.2%): reduction of depressive symptoms using psychosocial interventions for young adults only, and a combination of psychological and educational interventions in primary care had moderate credibility; preventive administration of selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in individuals with a stroke had high credibility. LIMITATIONS: Intervention heterogeneity and lack of long-term efficacy evaluation. CONCLUSIONS: Primary preventive interventions for depression might be effective. Among them, clinicians may offer SSRIs post-stroke to prevent depressive disorders, and psychosocial interventions for children/adolescents/young adults with risk factors or during the prenatal/pe

Published
2021

37. ENgage YOung people earlY (ENYOY): a mixed-method study design for a digital transdiagnostic clinical - and peer- moderated treatment platform for youth with beginning mental health complaints in the Netherlands.

Author

van Doorn, M, Popma, A, van Amelsvoort, T, McEnery, C, Gleeson, JF, Ory, FG, M W M, J, Alvarez-Jimenez, M, Nieman, DH, van Doorn, M, Popma, A, van Amelsvoort, T, McEnery, C, Gleeson, JF, Ory, FG, M W M, J, Alvarez-Jimenez, M, and Nieman, DH

Abstract

BACKGROUND: The onset of mental disorders typically occurs between the ages of 12 and 25, and the burden of mental health problems is the most consequential for this group. Indicated prevention interventions to target individuals with subclinical symptoms to prevent the transition to clinical levels of disorders, even leading to suicide, have shown to be effective. However, the threshold to seek help appears to be high. Digital interventions could offer a solution, especially during the Covid-19 pandemic. This implementation study will investigate the digital indicated prevention intervention ENgage YOung people Early (ENYOY), the Dutch version of the original Moderated Online Social Therapy Platform (MOST+) from Australia. In addition, the relationship between stress biomarkers, symptoms and outcome measures of youth using the platform will be investigated in this study. METHODS: The MOST+ platform will be adapted, translated and developed for the situation in the Netherlands in collaboration with a Youth Panel. A prospective cohort of 125 young people (16-25 years) with beginning mental health complaints will be on the platform and followed for a year, of which 10 participants will have an additional smart watch and 10 participants will be asked to provide feedback about the platform. Data will be collected at baseline and after 3, 6 and 12 months. Outcome measures are Psychological Distress assessed with the Kessler Psychological Distress Scale (K10), Social and occupational functioning (measures by the SOFAS), positive mental health indicators measured by the Positive Health Instrument, stress biomarkers with a smart-watch, website journeys of visitors, and feedback of youth about the platform. It will be a mixed-method study design, containing qualitative and quantitative measures. DISCUSSION: This trial will specifically address young people with emerging mental health complaints, and offers a new approach for treatment in the Netherlands. Considering the wait

Published
2021

38. Online Indicated Preventive Mental Health Interventions for Youth: A Scoping Review

Author

van Doorn, M, Nijhuis, LA, Egeler, MD, Daams, JG, Popma, A, van Amelsvoort, T, McEnery, C, Gleeson, JF, Ory, FG, Avis, KA, Ruigt, E, Jaspers, MWM, Alvarez-Jimenez, M, Nieman, DH, van Doorn, M, Nijhuis, LA, Egeler, MD, Daams, JG, Popma, A, van Amelsvoort, T, McEnery, C, Gleeson, JF, Ory, FG, Avis, KA, Ruigt, E, Jaspers, MWM, Alvarez-Jimenez, M, and Nieman, DH

Abstract

Objective: Between the ages of 12 and 25 the onset of mental disorders typically occurs, and the burden of mental health problems is greatest for this group. Indicated preventive interventions to target individuals with subclinical symptoms to prevent the transition to clinical levels of disorders have gained considerable traction. However, the threshold to seek help appears to be high even when help is needed. Online interventions could offer a solution, especially during the COVID-19 pandemic. This scoping review will present an overview of the recent research of indicated online preventive interventions for youth (12-25 years) experiencing the early stages of mental health complaints with the aim of identifying the nature and extent of the research evidence. Methods: The 5-stage framework by Arksey and O'Malley was used. Academic literature published from 2013 onwards in printed or electronic format was included from Scopus, PsychINFO, and Ovid MEDLINE(R) ALL. Results: The search yielded 11,122 results, with the final selection resulting in inclusion of 30 articles for this review. In total, the articles included 4,950 participants. 26.7% of the selected articles focused on youth between 12 and 25 years. Of the articles 60% did not screen for, nor exclude participants with clinical levels of symptoms. Most studies used a common evidence-based therapy for the disorder-category targeted. More than half of the online interventions included some form of human support. Adherence levels ranged between 27.9 and 98%. The results indicate general effectiveness, usability and acceptability of online indicated preventive interventions. The most commonly used approach was CBT (n = 12 studies). Studies varied in their size, rigor of study, effectiveness and outcome measures. Online interventions with a combination of clinical and peer moderation (n = 3 studies) appear to result in the most stable and highest effect sizes. Conclusion: Online indicated preventive mental health

Published
2021

39. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data.

Author

Merritt, K, McGuire, PK, Egerton, A, 1H-MRS in Schizophrenia Investigators, Aleman, A, Block, W, Bloemen, OJN, Borgan, F, Bustillo, JR, Capizzano, AA, Coughlin, JM, De la Fuente-Sandoval, C, Demjaha, A, Dempster, K, Do, KQ, Du, F, Falkai, P, Galinska-Skok, B, Gallinat, J, Gasparovic, C, Ginestet, CE, Goto, N, Graff-Guerrero, A, Ho, BC, Howes, OD, Jauhar, S, Jeon, P, Kato, T, Kaufmann, CA, Kegeles, LS, Keshavan, M, Kim, S-Y, Kunugi, H, Lauriello, J, Liemburg, EJ, Mcilwain, ME, Modinos, G, Mouchlianitis, ED, Nakamura, J, Nenadic, I, Öngür, D, Ota, M, Palaniyappan, L, Pantelis, C, Plitman, E, Posporelis, S, Purdon, SE, Reichenbach, JR, Renshaw, PF, Russell, BR, Sawa, A, Schaefer, M, Shungu, DC, Smesny, S, Stanley, JA, Stone, JM, Szulc, A, Taylor, R, Thakkar, K, Théberge, J, Tibbo, PG, van Amelsvoort, T, Walecki, J, Williamson, PC, Wood, SJ, Xin, L, Yamasue, H, Merritt, K, McGuire, PK, Egerton, A, 1H-MRS in Schizophrenia Investigators, Aleman, A, Block, W, Bloemen, OJN, Borgan, F, Bustillo, JR, Capizzano, AA, Coughlin, JM, De la Fuente-Sandoval, C, Demjaha, A, Dempster, K, Do, KQ, Du, F, Falkai, P, Galinska-Skok, B, Gallinat, J, Gasparovic, C, Ginestet, CE, Goto, N, Graff-Guerrero, A, Ho, BC, Howes, OD, Jauhar, S, Jeon, P, Kato, T, Kaufmann, CA, Kegeles, LS, Keshavan, M, Kim, S-Y, Kunugi, H, Lauriello, J, Liemburg, EJ, Mcilwain, ME, Modinos, G, Mouchlianitis, ED, Nakamura, J, Nenadic, I, Öngür, D, Ota, M, Palaniyappan, L, Pantelis, C, Plitman, E, Posporelis, S, Purdon, SE, Reichenbach, JR, Renshaw, PF, Russell, BR, Sawa, A, Schaefer, M, Shungu, DC, Smesny, S, Stanley, JA, Stone, JM, Szulc, A, Taylor, R, Thakkar, K, Théberge, J, Tibbo, PG, van Amelsvoort, T, Walecki, J, Williamson, PC, Wood, SJ, Xin, L, and Yamasue, H

Abstract

IMPORTANCE: Proton magnetic resonance spectroscopy (1H-MRS) studies indicate that altered brain glutamatergic function may be associated with the pathophysiology of schizophrenia and the response to antipsychotic treatment. However, the association of altered glutamatergic function with clinical and demographic factors is unclear. OBJECTIVE: To assess the associations of age, symptom severity, level of functioning, and antipsychotic treatment with brain glutamatergic metabolites. DATA SOURCES: The MEDLINE database was searched to identify journal articles published between January 1, 1980, and June 3, 2020, using the following search terms: MRS or magnetic resonance spectroscopy and (1) schizophrenia or (2) psychosis or (3) UHR or (4) ARMS or (5) ultra-high risk or (6) clinical high risk or (7) genetic high risk or (8) prodrome* or (9) schizoaffective. Authors of 114 1H-MRS studies measuring glutamate (Glu) levels in patients with schizophrenia were contacted between January 2014 and June 2020 and asked to provide individual participant data. STUDY SELECTION: In total, 45 1H-MRS studies contributed data. DATA EXTRACTION AND SYNTHESIS: Associations of Glu, Glu plus glutamine (Glx), or total creatine plus phosphocreatine levels with age, antipsychotic medication dose, symptom severity, and functioning were assessed using linear mixed models, with study as a random factor. MAIN OUTCOMES AND MEASURES: Glu, Glx, and Cr values in the medial frontal cortex (MFC) and medial temporal lobe (MTL). RESULTS: In total, 42 studies were included, with data for 1251 patients with schizophrenia (mean [SD] age, 30.3 [10.4] years) and 1197 healthy volunteers (mean [SD] age, 27.5 [8.8] years). The MFC Glu (F1,1211.9 = 4.311, P = .04) and Glx (F1,1079.2 = 5.287, P = .02) levels were lower in patients than in healthy volunteers, and although creatine levels appeared lower in patients, the difference was not significant (F1,1395.9 = 3.622, P = .06). In both patients and volunteers, the MFC

Published
2021

40. Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders

Author

Patel, Y, Parker, N, Shin, J, Howard, D, French, L, Thomopoulos, SI, Pozzi, E, Abe, Y, Abe, C, Anticevic, A, Alda, M, Aleman, A, Alloza, C, Alonso-Lana, S, Ameis, SH, Anagnostou, E, McIntosh, AA, Arango, C, Arnold, PD, Asherson, P, Assogna, F, Auzias, G, Ayesa-Arriola, R, Bakker, G, Banaj, N, Banaschewski, T, Bandeira, CE, Baranov, A, Bargallo, N, Bau, CHD, Baumeister, S, Baune, BT, Bellgrove, MA, Benedetti, F, Bertolino, A, Boedhoe, PSW, Boks, M, Bollettini, I, del Mar Bonnin, C, Borgers, T, Borgwardt, S, Brandeis, D, Brennan, BP, Bruggemann, JM, Bulow, R, Busatto, GF, Calderoni, S, Calhoun, VD, Calvo, R, Canales-Rodriguez, EJ, Cannon, DM, Carr, VJ, Cascella, N, Cercignani, M, Chaim-Avancini, TM, Christakou, A, Coghill, D, Conzelmann, A, Crespo-Facorro, B, Cubillo, AI, Cullen, KR, Cupertino, RB, Daly, E, Dannlowski, U, Davey, CG, Denys, D, Deruelle, C, Di Giorgio, A, Dickie, EW, Dima, D, Dohm, K, Ehrlich, S, Ely, BA, Erwin-Grabner, T, Ethofer, T, Fair, DA, Fallgatter, AJ, Faraone, SV, Fatjo-Vilas, M, Fedor, JM, Fitzgerald, KD, Ford, JM, Frodl, T, Fu, CHY, Fullerton, JM, Gabel, MC, Glahn, DC, Roberts, G, Gogberashvili, T, Goikolea, JM, Gotlib, IH, Goya-Maldonado, R, Grabe, HJ, Green, MJ, Grevet, EH, Groenewold, NA, Grotegerd, D, Gruber, O, Gruner, P, Guerrero-Pedraza, A, Gur, RE, Gur, RC, Haar, S, Haarman, BCM, Haavik, J, Hahn, T, Hajek, T, Harrison, BJ, Harrison, NA, Hartman, CA, Whalley, HC, Heslenfeld, DJ, Hibar, DP, Hilland, E, Hirano, Y, Ho, TC, Hoekstra, PJ, Hoekstra, L, Hohmann, S, Hong, LE, Hoschl, C, Hovik, MF, Howells, FM, Nenadic, I, Jalbrzikowski, M, James, AC, Janssen, J, Jaspers-Fayer, F, Xu, J, Jonassen, R, Karkashadze, G, King, JA, Kircher, T, Kirschner, M, Koch, K, Kochunov, P, Kohls, G, Konrad, K, Kramer, B, Krug, A, Kuntsi, J, Kwon, JS, Landen, M, Landro, NI, Lazaro, L, Lebedeva, IS, Leehr, EJ, Lera-Miguel, S, Lesch, K-P, Lochner, C, Louza, MR, Luna, B, Lundervold, AJ, MacMaster, FP, Maglanoc, LA, Malpas, CB, Portella, MJ, Marsh, R, Martyn, FM, Mataix-Cols, D, Mathalon, DH, McCarthy, H, McDonald, C, McPhilemy, G, Meinert, S, Menchon, JM, Minuzzi, L, Mitchell, PB, Moreno, C, Morgado, P, Muratori, F, Murphy, CM, Murphy, D, Mwangi, B, Nabulsi, L, Nakagawa, A, Nakamae, T, Namazova, L, Narayanaswamy, J, Jahanshad, N, Nguyen, DD, Nicolau, R, O'Gorman Tuura, RL, O'Hearn, K, Oosterlaan, J, Opel, N, Ophoff, RA, Oranje, B, Garcia de la Foz, VO, Overs, BJ, Paloyelis, Y, Pantelis, C, Parellada, M, Pauli, P, Pico-Perez, M, Picon, FA, Piras, F, Plessen, KJ, Pomarol-Clotet, E, Preda, A, Puig, O, Quide, Y, Radua, J, Ramos-Quiroga, JA, Rasser, PE, Rauer, L, Reddy, J, Redlich, R, Reif, A, Reneman, L, Repple, J, Retico, A, Richarte, V, Richter, A, Rosa, PGP, Rubia, KK, Hashimoto, R, Sacchet, MD, Salvador, R, Santonja, J, Sarink, K, Sarro, S, Satterthwaite, TD, Sawa, A, Schall, U, Schofield, PR, Schrantee, A, Seitz, J, Serpa, MH, Setien-Suero, E, Shaw, P, Shook, D, Silk, TJ, Sim, K, Simon, S, Simpson, HB, Singh, A, Skoch, A, Skokauskas, N, Soares, JC, Soreni, N, Soriano-Mas, C, Spalletta, G, Spaniel, F, Lawrie, SM, Stern, ER, Stewart, SE, Takayanagi, Y, Temmingh, HS, Tolin, DF, Tomecek, D, Tordesillas-Gutierrez, D, Tosetti, M, Uhlmann, A, van Amelsvoort, T, van der Wee, NJA, van der Werff, SJA, van Haren, NEM, van Wingen, GA, Vance, A, Vazquez-Bourgon, J, Vecchio, D, Venkatasubramanian, G, Vieta, E, Vilarroya, O, Vives-Gilabert, Y, Voineskos, AN, Volzke, H, von Polier, GG, Walton, E, Weickert, TW, Weickert, CS, Weideman, AS, Wittfeld, K, Wolf, DH, Wu, M-J, Yang, TT, Yang, K, Yoncheva, Y, Yun, J-Y, Cheng, Y, Zanetti, MV, Ziegler, GC, Franke, B, Hoogman, M, Buitelaar, JK, van Rooij, D, Andreassen, OA, Ching, CRK, Veltman, DJ, Schmaal, L, Stein, DJ, van den Heuvel, OA, Turner, JA, van Erp, TGM, Pausova, Z, Thompson, PM, Paus, T, Patel, Y, Parker, N, Shin, J, Howard, D, French, L, Thomopoulos, SI, Pozzi, E, Abe, Y, Abe, C, Anticevic, A, Alda, M, Aleman, A, Alloza, C, Alonso-Lana, S, Ameis, SH, Anagnostou, E, McIntosh, AA, Arango, C, Arnold, PD, Asherson, P, Assogna, F, Auzias, G, Ayesa-Arriola, R, Bakker, G, Banaj, N, Banaschewski, T, Bandeira, CE, Baranov, A, Bargallo, N, Bau, CHD, Baumeister, S, Baune, BT, Bellgrove, MA, Benedetti, F, Bertolino, A, Boedhoe, PSW, Boks, M, Bollettini, I, del Mar Bonnin, C, Borgers, T, Borgwardt, S, Brandeis, D, Brennan, BP, Bruggemann, JM, Bulow, R, Busatto, GF, Calderoni, S, Calhoun, VD, Calvo, R, Canales-Rodriguez, EJ, Cannon, DM, Carr, VJ, Cascella, N, Cercignani, M, Chaim-Avancini, TM, Christakou, A, Coghill, D, Conzelmann, A, Crespo-Facorro, B, Cubillo, AI, Cullen, KR, Cupertino, RB, Daly, E, Dannlowski, U, Davey, CG, Denys, D, Deruelle, C, Di Giorgio, A, Dickie, EW, Dima, D, Dohm, K, Ehrlich, S, Ely, BA, Erwin-Grabner, T, Ethofer, T, Fair, DA, Fallgatter, AJ, Faraone, SV, Fatjo-Vilas, M, Fedor, JM, Fitzgerald, KD, Ford, JM, Frodl, T, Fu, CHY, Fullerton, JM, Gabel, MC, Glahn, DC, Roberts, G, Gogberashvili, T, Goikolea, JM, Gotlib, IH, Goya-Maldonado, R, Grabe, HJ, Green, MJ, Grevet, EH, Groenewold, NA, Grotegerd, D, Gruber, O, Gruner, P, Guerrero-Pedraza, A, Gur, RE, Gur, RC, Haar, S, Haarman, BCM, Haavik, J, Hahn, T, Hajek, T, Harrison, BJ, Harrison, NA, Hartman, CA, Whalley, HC, Heslenfeld, DJ, Hibar, DP, Hilland, E, Hirano, Y, Ho, TC, Hoekstra, PJ, Hoekstra, L, Hohmann, S, Hong, LE, Hoschl, C, Hovik, MF, Howells, FM, Nenadic, I, Jalbrzikowski, M, James, AC, Janssen, J, Jaspers-Fayer, F, Xu, J, Jonassen, R, Karkashadze, G, King, JA, Kircher, T, Kirschner, M, Koch, K, Kochunov, P, Kohls, G, Konrad, K, Kramer, B, Krug, A, Kuntsi, J, Kwon, JS, Landen, M, Landro, NI, Lazaro, L, Lebedeva, IS, Leehr, EJ, Lera-Miguel, S, Lesch, K-P, Lochner, C, Louza, MR, Luna, B, Lundervold, AJ, MacMaster, FP, Maglanoc, LA, Malpas, CB, Portella, MJ, Marsh, R, Martyn, FM, Mataix-Cols, D, Mathalon, DH, McCarthy, H, McDonald, C, McPhilemy, G, Meinert, S, Menchon, JM, Minuzzi, L, Mitchell, PB, Moreno, C, Morgado, P, Muratori, F, Murphy, CM, Murphy, D, Mwangi, B, Nabulsi, L, Nakagawa, A, Nakamae, T, Namazova, L, Narayanaswamy, J, Jahanshad, N, Nguyen, DD, Nicolau, R, O'Gorman Tuura, RL, O'Hearn, K, Oosterlaan, J, Opel, N, Ophoff, RA, Oranje, B, Garcia de la Foz, VO, Overs, BJ, Paloyelis, Y, Pantelis, C, Parellada, M, Pauli, P, Pico-Perez, M, Picon, FA, Piras, F, Plessen, KJ, Pomarol-Clotet, E, Preda, A, Puig, O, Quide, Y, Radua, J, Ramos-Quiroga, JA, Rasser, PE, Rauer, L, Reddy, J, Redlich, R, Reif, A, Reneman, L, Repple, J, Retico, A, Richarte, V, Richter, A, Rosa, PGP, Rubia, KK, Hashimoto, R, Sacchet, MD, Salvador, R, Santonja, J, Sarink, K, Sarro, S, Satterthwaite, TD, Sawa, A, Schall, U, Schofield, PR, Schrantee, A, Seitz, J, Serpa, MH, Setien-Suero, E, Shaw, P, Shook, D, Silk, TJ, Sim, K, Simon, S, Simpson, HB, Singh, A, Skoch, A, Skokauskas, N, Soares, JC, Soreni, N, Soriano-Mas, C, Spalletta, G, Spaniel, F, Lawrie, SM, Stern, ER, Stewart, SE, Takayanagi, Y, Temmingh, HS, Tolin, DF, Tomecek, D, Tordesillas-Gutierrez, D, Tosetti, M, Uhlmann, A, van Amelsvoort, T, van der Wee, NJA, van der Werff, SJA, van Haren, NEM, van Wingen, GA, Vance, A, Vazquez-Bourgon, J, Vecchio, D, Venkatasubramanian, G, Vieta, E, Vilarroya, O, Vives-Gilabert, Y, Voineskos, AN, Volzke, H, von Polier, GG, Walton, E, Weickert, TW, Weickert, CS, Weideman, AS, Wittfeld, K, Wolf, DH, Wu, M-J, Yang, TT, Yang, K, Yoncheva, Y, Yun, J-Y, Cheng, Y, Zanetti, MV, Ziegler, GC, Franke, B, Hoogman, M, Buitelaar, JK, van Rooij, D, Andreassen, OA, Ching, CRK, Veltman, DJ, Schmaal, L, Stein, DJ, van den Heuvel, OA, Turner, JA, van Erp, TGM, Pausova, Z, Thompson, PM, and Paus, T

Abstract

IMPORTANCE: Large-scale neuroimaging studies have revealed group differences in cortical thickness across many psychiatric disorders. The underlying neurobiology behind these differences is not well understood. OBJECTIVE: To determine neurobiologic correlates of group differences in cortical thickness between cases and controls in 6 disorders: attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder (BD), major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: Profiles of group differences in cortical thickness between cases and controls were generated using T1-weighted magnetic resonance images. Similarity between interregional profiles of cell-specific gene expression and those in the group differences in cortical thickness were investigated in each disorder. Next, principal component analysis was used to reveal a shared profile of group difference in thickness across the disorders. Analysis for gene coexpression, clustering, and enrichment for genes associated with these disorders were conducted. Data analysis was conducted between June and December 2019. The analysis included 145 cohorts across 6 psychiatric disorders drawn from the ENIGMA consortium. The numbers of cases and controls in each of the 6 disorders were as follows: ADHD: 1814 and 1602; ASD: 1748 and 1770; BD: 1547 and 3405; MDD: 2658 and 3572; OCD: 2266 and 2007; and schizophrenia: 2688 and 3244. MAIN OUTCOMES AND MEASURES: Interregional profiles of group difference in cortical thickness between cases and controls. RESULTS: A total of 12 721 cases and 15 600 controls, ranging from ages 2 to 89 years, were included in this study. Interregional profiles of group differences in cortical thickness for each of the 6 psychiatric disorders were associated with profiles of gene expression specific to pyramidal (CA1) cells, astrocytes (except for BD), and microglia (except for OCD); collectively, gene

Published
2021

41. Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders

Author

Patel, Y., Parker, N., Shin, J., Howard, D., French, L., Thomopoulos, S.I., Pozzi, E., Abe, Y., Abé, C., Anticevic, A., Alda, M., Aleman, A., Alloza, C., Alonso-Lana, S., Ameis, S.H., Anagnostou, E., McIntosh, A.A., Arango, C., Arnold, P.D., Asherson, P., Assogna, F., Auzias, G., Ayesa-Arriola, R., Bakker, G., Banaj, N., Banaschewski, T., Bandeira, C.E., Baranov, A., Bargalló, N., Bau, C.H.D., Baumeister, S., Baune, B.T., Bellgrove, M.A., Benedetti, F., Bertolino, A., Boedhoe, P.S.W., Boks, M., Bollettini, I., Del Mar Bonnin, C., Borgers, T., Borgwardt, S., Brandeis, D., Brennan, B.P., Bruggemann, J.M., Bülow, R., Busatto, G.F., Calderoni, S., Calhoun, V.D., Calvo, R., Canales-Rodríguez, E.J., Cannon, D.M., Carr, V.J., Cascella, N., Cercignani, M., Chaim-Avancini, T.M., Christakou, A., Coghill, D., Conzelmann, A., Crespo-Facorro, B., Cubillo, A.I., Cullen, K.R., Cupertino, R.B., Daly, E., Dannlowski, U., Davey, C.G., Denys, D., Deruelle, C., Di Giorgio, A., Dickie, E.W., Dima, D., Dohm, K., Ehrlich, S., Ely, B.A., Erwin-Grabner, T., Ethofer, T., Fair, D.A., Fallgatter, A.J., Faraone, S.V., Fatjó-Vilas, M., Fedor, J.M., Fitzgerald, K.D., Ford, J.M., Frodl, T., Fu, C.H.Y., Fullerton, J.M., Gabel, M.C., Glahn, D.C., Roberts, G., Gogberashvili, T., Goikolea, J.M., Gotlib, I.H., Goya-Maldonado, R., Grabe, H.J., Green, M.J., Grevet, E.H., Groenewold, N.A., Grotegerd, D., Gruber, O., Gruner, P., Guerrero-Pedraza, A., Gur, R.E., Gur, R.C., Haar, S., Haarman, B.C.M., Haavik, J., Hahn, T., Hajek, T., Harrison, B.J., Harrison, N.A., Hartman, C.A., Whalley, H.C., Heslenfeld, D.J., Hibar, D.P., Hilland, E., Hirano, Y., Ho, T.C., Hoekstra, P.J., Hoekstra, L., Hohmann, S., Hong, L.E., Höschl, C., Høvik, M.F., Howells, F.M., Nenadic, I., Jalbrzikowski, M., James, A.C., Janssen, J., Jaspers-Fayer, F., Xu, J., Jonassen, R., Karkashadze, G., King, J.A., Kircher, T., Kirschner, M., Koch, K., Kochunov, P., Kohls, G., Konrad, K., Krämer, B., Krug, A., Kuntsi, J., Kwon, J.S., Landén, M., Landrø, N.I., Lazaro, L., Lebedeva, I.S., Leehr, E.J., Lera-Miguel, S., Lesch, K.-P., Lochner, C., Louza, M.R., Luna, B., Lundervold, A.J., Macmaster, F.P., Maglanoc, L.A., Malpas, C.B., Portella, M.J., Marsh, R., Martyn, F.M., Mataix-Cols, D., Mathalon, D.H., McCarthy, H., McDonald, C., McPhilemy, G., Meinert, S., Menchón, J.M., Minuzzi, L., Mitchell, P.B., Moreno, C., Morgado, P., Muratori, F., Murphy, C.M., Murphy, D., Mwangi, B., Nabulsi, L., Nakagawa, A., Nakamae, T., Namazova, L., Narayanaswamy, J., Jahanshad, N., Nguyen, D.D., Nicolau, R., O'Gorman Tuura, R.L., O'Hearn, K., Oosterlaan, J., Opel, N., Ophoff, R.A., Oranje, B., García De La Foz, V.O., Overs, B.J., Paloyelis, Y., Pantelis, C., Parellada, M., Pauli, P., Picó-Pérez, M., Picon, F.A., Piras, F., Plessen, K.J., Pomarol-Clotet, E., Preda, A., Puig, O., Quidé, Y., Radua, J., Ramos-Quiroga, J.A., Rasser, P.E., Rauer, L., Reddy, J., Redlich, R., Reif, A., Reneman, L., Repple, J., Retico, A., Richarte, V., Richter, A., Rosa, P.G.P., Rubia, K.K., Hashimoto, R., Sacchet, M.D., Salvador, R., Santonja, J., Sarink, K., Sarró, S., Satterthwaite, T.D., Sawa, A., Schall, U., Schofield, P.R., Schrantee, A., Seitz, J., Serpa, M.H., Setién-Suero, E., Shaw, P., Shook, D., Silk, T.J., Sim, K., Simon, S., Simpson, H.B., Singh, A., Skoch, A., Skokauskas, N., Soares, J.C., Soreni, N., Soriano-Mas, C., Spalletta, G., Spaniel, F., Lawrie, S.M., Stern, E.R., Stewart, S.E., Takayanagi, Y., Temmingh, H.S., Tolin, D.F., Tomecek, D., Tordesillas-Gutiérrez, D., Tosetti, M., Uhlmann, A., Van Amelsvoort, T., Van Der Wee, N.J.A., Van Der Werff, S.J.A., Van Haren, N.E.M., Van Wingen, G.A., Vance, A., Vázquez-Bourgon, J., Vecchio, D., Venkatasubramanian, G., Vieta, E., Vilarroya, O., Vives-Gilabert, Y., Voineskos, A.N., Völzke, H., Von Polier, G.G., Walton, E., Weickert, T.W., Weickert, C.S., Weideman, A.S., Wittfeld, K., Wolf, D.H., Wu, M.-J., Yang, T.T., Yang, K., Yoncheva, Y., Yun, J.-Y., Cheng, Y., Zanetti, M.V., Ziegler, G.C., Franke, B., Hoogman, M., Buitelaar, J.K., Van Rooij, D., Andreassen, O.A., Ching, C.R.K., Veltman, D.J., Schmaal, L., Stein, D.J., Van Den Heuvel, O.A., Turner, J.A., Van Erp, T.G.M., Pausova, Z., Thompson, P.M., Paus, T., Patel, Y., Parker, N., Shin, J., Howard, D., French, L., Thomopoulos, S.I., Pozzi, E., Abe, Y., Abé, C., Anticevic, A., Alda, M., Aleman, A., Alloza, C., Alonso-Lana, S., Ameis, S.H., Anagnostou, E., McIntosh, A.A., Arango, C., Arnold, P.D., Asherson, P., Assogna, F., Auzias, G., Ayesa-Arriola, R., Bakker, G., Banaj, N., Banaschewski, T., Bandeira, C.E., Baranov, A., Bargalló, N., Bau, C.H.D., Baumeister, S., Baune, B.T., Bellgrove, M.A., Benedetti, F., Bertolino, A., Boedhoe, P.S.W., Boks, M., Bollettini, I., Del Mar Bonnin, C., Borgers, T., Borgwardt, S., Brandeis, D., Brennan, B.P., Bruggemann, J.M., Bülow, R., Busatto, G.F., Calderoni, S., Calhoun, V.D., Calvo, R., Canales-Rodríguez, E.J., Cannon, D.M., Carr, V.J., Cascella, N., Cercignani, M., Chaim-Avancini, T.M., Christakou, A., Coghill, D., Conzelmann, A., Crespo-Facorro, B., Cubillo, A.I., Cullen, K.R., Cupertino, R.B., Daly, E., Dannlowski, U., Davey, C.G., Denys, D., Deruelle, C., Di Giorgio, A., Dickie, E.W., Dima, D., Dohm, K., Ehrlich, S., Ely, B.A., Erwin-Grabner, T., Ethofer, T., Fair, D.A., Fallgatter, A.J., Faraone, S.V., Fatjó-Vilas, M., Fedor, J.M., Fitzgerald, K.D., Ford, J.M., Frodl, T., Fu, C.H.Y., Fullerton, J.M., Gabel, M.C., Glahn, D.C., Roberts, G., Gogberashvili, T., Goikolea, J.M., Gotlib, I.H., Goya-Maldonado, R., Grabe, H.J., Green, M.J., Grevet, E.H., Groenewold, N.A., Grotegerd, D., Gruber, O., Gruner, P., Guerrero-Pedraza, A., Gur, R.E., Gur, R.C., Haar, S., Haarman, B.C.M., Haavik, J., Hahn, T., Hajek, T., Harrison, B.J., Harrison, N.A., Hartman, C.A., Whalley, H.C., Heslenfeld, D.J., Hibar, D.P., Hilland, E., Hirano, Y., Ho, T.C., Hoekstra, P.J., Hoekstra, L., Hohmann, S., Hong, L.E., Höschl, C., Høvik, M.F., Howells, F.M., Nenadic, I., Jalbrzikowski, M., James, A.C., Janssen, J., Jaspers-Fayer, F., Xu, J., Jonassen, R., Karkashadze, G., King, J.A., Kircher, T., Kirschner, M., Koch, K., Kochunov, P., Kohls, G., Konrad, K., Krämer, B., Krug, A., Kuntsi, J., Kwon, J.S., Landén, M., Landrø, N.I., Lazaro, L., Lebedeva, I.S., Leehr, E.J., Lera-Miguel, S., Lesch, K.-P., Lochner, C., Louza, M.R., Luna, B., Lundervold, A.J., Macmaster, F.P., Maglanoc, L.A., Malpas, C.B., Portella, M.J., Marsh, R., Martyn, F.M., Mataix-Cols, D., Mathalon, D.H., McCarthy, H., McDonald, C., McPhilemy, G., Meinert, S., Menchón, J.M., Minuzzi, L., Mitchell, P.B., Moreno, C., Morgado, P., Muratori, F., Murphy, C.M., Murphy, D., Mwangi, B., Nabulsi, L., Nakagawa, A., Nakamae, T., Namazova, L., Narayanaswamy, J., Jahanshad, N., Nguyen, D.D., Nicolau, R., O'Gorman Tuura, R.L., O'Hearn, K., Oosterlaan, J., Opel, N., Ophoff, R.A., Oranje, B., García De La Foz, V.O., Overs, B.J., Paloyelis, Y., Pantelis, C., Parellada, M., Pauli, P., Picó-Pérez, M., Picon, F.A., Piras, F., Plessen, K.J., Pomarol-Clotet, E., Preda, A., Puig, O., Quidé, Y., Radua, J., Ramos-Quiroga, J.A., Rasser, P.E., Rauer, L., Reddy, J., Redlich, R., Reif, A., Reneman, L., Repple, J., Retico, A., Richarte, V., Richter, A., Rosa, P.G.P., Rubia, K.K., Hashimoto, R., Sacchet, M.D., Salvador, R., Santonja, J., Sarink, K., Sarró, S., Satterthwaite, T.D., Sawa, A., Schall, U., Schofield, P.R., Schrantee, A., Seitz, J., Serpa, M.H., Setién-Suero, E., Shaw, P., Shook, D., Silk, T.J., Sim, K., Simon, S., Simpson, H.B., Singh, A., Skoch, A., Skokauskas, N., Soares, J.C., Soreni, N., Soriano-Mas, C., Spalletta, G., Spaniel, F., Lawrie, S.M., Stern, E.R., Stewart, S.E., Takayanagi, Y., Temmingh, H.S., Tolin, D.F., Tomecek, D., Tordesillas-Gutiérrez, D., Tosetti, M., Uhlmann, A., Van Amelsvoort, T., Van Der Wee, N.J.A., Van Der Werff, S.J.A., Van Haren, N.E.M., Van Wingen, G.A., Vance, A., Vázquez-Bourgon, J., Vecchio, D., Venkatasubramanian, G., Vieta, E., Vilarroya, O., Vives-Gilabert, Y., Voineskos, A.N., Völzke, H., Von Polier, G.G., Walton, E., Weickert, T.W., Weickert, C.S., Weideman, A.S., Wittfeld, K., Wolf, D.H., Wu, M.-J., Yang, T.T., Yang, K., Yoncheva, Y., Yun, J.-Y., Cheng, Y., Zanetti, M.V., Ziegler, G.C., Franke, B., Hoogman, M., Buitelaar, J.K., Van Rooij, D., Andreassen, O.A., Ching, C.R.K., Veltman, D.J., Schmaal, L., Stein, D.J., Van Den Heuvel, O.A., Turner, J.A., Van Erp, T.G.M., Pausova, Z., Thompson, P.M., and Paus, T.

Abstract

Importance Large-scale neuroimaging studies have revealed group differences in cortical thickness across many psychiatric disorders. The underlying neurobiology behind these differences is not well understood. Objective To determine neurobiologic correlates of group differences in cortical thickness between cases and controls in 6 disorders: attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder (BD), major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and schizophrenia. Design, Setting, and Participants Profiles of group differences in cortical thickness between cases and controls were generated using T1-weighted magnetic resonance images. Similarity between interregional profiles of cell-specific gene expression and those in the group differences in cortical thickness were investigated in each disorder. Next, principal component analysis was used to reveal a shared profile of group difference in thickness across the disorders. Analysis for gene coexpression, clustering, and enrichment for genes associated with these disorders were conducted. Data analysis was conducted between June and December 2019. The analysis included 145 cohorts across 6 psychiatric disorders drawn from the ENIGMA consortium. The numbers of cases and controls in each of the 6 disorders were as follows: ADHD: 1814 and 1602; ASD: 1748 and 1770; BD: 1547 and 3405; MDD: 2658 and 3572; OCD: 2266 and 2007; and schizophrenia: 2688 and 3244. Main Outcomes and Measures Interregional profiles of group difference in cortical thickness between cases and controls. Results A total of 12 721 cases and 15 600 controls, ranging from ages 2 to 89 years, were included in this study. Interregional profiles of group differences in cortical thickness for each of the 6 psychiatric disorders were associated with profiles of gene expression specific to pyramidal (CA1) cells, astrocytes (except for BD), and microglia (exce

Published
2021
Full Text
View/download PDF

42. Using common genetic variation to examine phenotypic expression and risk prediction in 22q11.2 deletion syndrome

Author

Davies, R. W., Fiksinski, A. M., Breetvelt, E. J., Williams, N. M., Hooper, S. R., Monfeuga, T., Bassett, A. S., Owen, M. J., Gur, R. E., Morrow, B. E., McDonald-McGinn, D. M., Swillen, A., Chow, E. W. C., van den Bree, M., Emanuel, B. S., Vermeesch, J. R., van Amelsvoort, T., Arango, C., Armando, M., Campbell, L. E., Cubells, J. F., Eliez, S., Garcia-Minaur, S., Gothelf, D., Kates, W. R., Murphy, K. C., Murphy, C. M., Murphy, D. G., Philip, N., Repetto, G. M., Shashi, V., Simon, T. J., Suner, D. H., Vicari, Stefano, Scherer, S. W., Epstein, M. P., Warren, S. T., Morrison, S., Chawner, S., Vingerhoets, C., Breckpot, J., Vergaelen, E., Vogels, A., Monks, S., Prasad, S. E., Sandini, C., Schneider, M., Maeder, J., Fraguas, D., Evers, R., Tassone, F., Morey-Canyelles, J., Ousley, O. Y., Antshel, K. M., Fremont, W., Fritsch, R., Ornstein, C., Daly, E. M., Costain, G. A., Boot, E., Heung, T., Crowley, T. B., Zackai, E. H., Calkins, M. E., Gur, R. C., Mccabe, K. L., Busa, T., Schoch, K., Pontillo, M., Duijff, S. N., Kahn, R. S., Houben, Mariasofia, Kushan, L., Jalbrzikowski, M., Carmel, M., Mekori-Domachevsky, E., Michaelovsky, E., Weinberger, R., Bearden, C. E., Vorstman, J. A. S., Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de génétique médicale [Hôpital de la Timone - APHM], Institut National de la Santé et de la Recherche Médicale (INSERM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU), RS: MHeNs - R2 - Mental Health, Psychiatrie & Neuropsychologie, and MUMC+: MA Med Staf Spec Psychiatrie (9)

Subjects
0301 basic medicine, Male, Multifactorial Inheritance, [SDV]Life Sciences [q-bio], INTELLIGENCE, Medical and Health Sciences, Cohort Studies, ddc:616.89, 0302 clinical medicine, Borderline intellectual functioning, Risk Factors, Intellectual disability, 2.1 Biological and endogenous factors, PREMORBID IQ, Cognitive decline, Aetiology, Child, ComputingMilieux_MISCELLANEOUS, Intelligence quotient, ABNORMALITIES, General Medicine, Middle Aged, Serious Mental Illness, Mental Health, Phenotype, Schizophrenia, 030220 oncology & carcinogenesis, Child, Preschool, Cohort, Female, Clinical psychology, Adult, Psychosis, Adolescent, Immunology, behavioral disciplines and activities, General Biochemistry, Genetics and Molecular Biology, Article, 03 medical and health sciences, Young Adult, Settore MED/39 - NEUROPSICHIATRIA INFANTILE, PSYCHOSIS, Clinical Research, Intellectual Disability, Genetic variation, Behavioral and Social Science, mental disorders, medicine, Genetics, DiGeorge Syndrome, Humans, Cognitive Dysfunction, Preschool, METAANALYSIS, International 22q11.2 Brain and Behavior Consortium, Aged, DECLINE, reliability, business.industry, Prevention, cognitive-development, Genetic Variation, PERFORMANCE, medicine.disease, Brain Disorders, schizophrenia, 030104 developmental biology, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, business
Abstract

The 22q11.2 deletion syndrome (22q11DS) is associated with a 20-25% risk of schizophrenia. In a cohort of 962 individuals with 22q11DS, we examined the shared genetic basis between schizophrenia and schizophrenia-related early trajectory phenotypes: sub-threshold symptoms of psychosis, low baseline intellectual functioning and cognitive decline. We studied the association of these phenotypes with two polygenic scores, derived for schizophrenia and intelligence, and evaluated their use for individual risk prediction in 22q11DS. Polygenic scores were not only associated with schizophrenia and baseline intelligence quotient (IQ), respectively, but schizophrenia polygenic score was also significantly associated with cognitive (verbal IQ) decline and nominally associated with sub-threshold psychosis. Furthermore, in comparing the tail-end deciles of the schizophrenia and IQ polygenic score distributions, 33% versus 9% of individuals with 22q11DS had schizophrenia, and 63% versus 24% of individuals had intellectual disability. Collectively, these data show a shared genetic basis for schizophrenia and schizophrenia-related phenotypes and also highlight the future potential of polygenic scores for risk stratification among individuals with highly, but incompletely, penetrant genetic variants.Polygenic risk scores are nearing a level of differentiation required for their clinical utility in risk prediction in populations with high-risk rare pathogenic genetic variants.

Published
2020

47. An ecological momentary compassion-focused intervention for enhancing resilience in help-seeking youths: a pilot study

Author

Christian Rauschenberg, van Amelsvoort T, Böcking B, Reininghaus U, Pätzold I, Schruers K, and Anita Schick

Subjects
media_common.quotation_subject, Intervention (counseling), Applied psychology, Compassion, Psychology, Resilience (network), Help-seeking, media_common
Abstract

Digital interventions offer new avenues for prevention and treatment in youth. Ecological momentary interventions (EMIs) allow for adaptive and real-time delivery of intervention components in daily life. Compassion-focused interventions may be particularly amenable to translation into an EMI to strengthen emotional resilience in youth. We aimed to investigate initial therapeutic effects, feasibility, and safety of a novel, accessible, transdiagnostic, ecological momentary, compassion-focused intervention for improving emotional resilience (‘EMIcompass’) in an uncontrolled pilot study including help-seeking youth with psychotic, depressive, and/or anxiety symptoms. The EMIcompass intervention consisted of three sessions with a trained psychologist and a 3-week EMI administered through a mobile health app. In total, ten individuals (Mage=20.3 years) were included. Reduced stress sensitivity, momentary negative affect, and psychotic experiences as well as increased positive affect were found at post-intervention and 4-week follow-up. Further, reductions in psychotic, anxiety, and depressive symptoms of medium to large effect size were found (r=0.30-0.65). Most participants were satisfied (80%) and reported low burden of app usage. No adverse events were observed. Our findings provide initial evidence on beneficial effects, feasibility, and safety of the EMIcompass intervention in help-seeking youth. An exploratory randomised controlled trial is warranted to establish feasibility and preliminary evidence of efficacy.

Published
2020

48. Ten years of infant mental health in the Netherlands: Who are the clients?

Author

Dekelver, H., Hoekstra, A., van Bakel, H. J. A., Marchetta, N., van Amelsvoort, T. A. M. J., Tranzo, Scientific center for care and wellbeing, and Jeugd

Abstract

Background: Infant Mental Health (IMH) is a topic of current interest that emerged over the past decades, concerned with alleviating suffering and enhancing the social and emotional competence of young children. Worldwide there is increasing recognition of infant psychopathology meriting intervention. However, there are still limited data regarding the prevalence of psychiatric disorders and sociodemographic characteristics of these youngest of patients in clinical settings. Aim: This large, descriptive study aims at presenting the socio-demographic and clinical characteristics of infants referred consecutively to three outpatient Infant Mental Health teams in the Netherlands between September 2000 and July 2013. Methods: The medical records of 783 infants were retrospectively examined and the data were collected from paper and electronic patient files. Clinical and socio-demographic characteristics were categorized in child factors, developmental milestones, family factors and clinical outcome measures (DSM-IV, DC:0-3R, WIPPSI-III, SON-R 2½-7). Results: Our sample showed significantly more boys (543, 69%) than girls (240, 31%) being referred to the Infant Mental Health teams. Most children were referred when they were four or five years of age, both boys and girls. Mean duration of treatment was about a year and a half (20.34 months, SD 18.87) and most reported diagnoses were ADHD/behavioral disorders, ASS and disorder in infancy/childhood NOS. Familial psychiatric disorders were reported in 242 families (41%). These findings are discussed in the light of earlier research.

Published
2020

49. Increased power by harmonizing structural MRI site differences with the ComBat batch adjustment method in ENIGMA

Author

Radua, J, Vieta, E, Shinohara, R, Kochunov, P, Quidé, Y, Green, MJ, Weickert, CS, Weickert, T, Bruggemann, J, Kircher, T, Nenadić, I, Cairns, MJ, Seal, M, Schall, U, Henskens, F, Fullerton, JM, Mowry, B, Pantelis, C, Lenroot, R, Cropley, V, Loughland, C, Scott, R, Wolf, D, Satterthwaite, TD, Tan, Y, Sim, K, Piras, F, Spalletta, G, Banaj, N, Pomarol-Clotet, E, Solanes, A, Albajes-Eizagirre, A, Canales-Rodríguez, EJ, Sarro, S, Di Giorgio, A, Bertolino, A, Stäblein, M, Oertel, V, Knöchel, C, Borgwardt, S, du Plessis, S, Yun, JY, Kwon, JS, Dannlowski, U, Hahn, T, Grotegerd, D, Alloza, C, Arango, C, Janssen, J, Díaz-Caneja, C, Jiang, W, Calhoun, V, Ehrlich, S, Yang, K, Cascella, NG, Takayanagi, Y, Sawa, A, Tomyshev, A, Lebedeva, I, Kaleda, V, Kirschner, M, Hoschl, C, Tomecek, D, Skoch, A, van Amelsvoort, T, Bakker, G, James, A, Preda, A, Weideman, A, Stein, DJ, Howells, F, Uhlmann, A, Temmingh, H, López-Jaramillo, C, Díaz-Zuluaga, A, Fortea, L, Martinez-Heras, E, Solana, E, Llufriu, S, Jahanshad, N, Thompson, P, Turner, J, van Erp, T, Glahn, D, Pearlson, G, Hong, E, Krug, A, Carr, V, Tooney, P, Cooper, G, Rasser, P, Michie, P, Catts, S, Gur, R, Yang, F, Fan, F, Chen, J, Guo, H, Tan, S, Radua, J, Vieta, E, Shinohara, R, Kochunov, P, Quidé, Y, Green, MJ, Weickert, CS, Weickert, T, Bruggemann, J, Kircher, T, Nenadić, I, Cairns, MJ, Seal, M, Schall, U, Henskens, F, Fullerton, JM, Mowry, B, Pantelis, C, Lenroot, R, Cropley, V, Loughland, C, Scott, R, Wolf, D, Satterthwaite, TD, Tan, Y, Sim, K, Piras, F, Spalletta, G, Banaj, N, Pomarol-Clotet, E, Solanes, A, Albajes-Eizagirre, A, Canales-Rodríguez, EJ, Sarro, S, Di Giorgio, A, Bertolino, A, Stäblein, M, Oertel, V, Knöchel, C, Borgwardt, S, du Plessis, S, Yun, JY, Kwon, JS, Dannlowski, U, Hahn, T, Grotegerd, D, Alloza, C, Arango, C, Janssen, J, Díaz-Caneja, C, Jiang, W, Calhoun, V, Ehrlich, S, Yang, K, Cascella, NG, Takayanagi, Y, Sawa, A, Tomyshev, A, Lebedeva, I, Kaleda, V, Kirschner, M, Hoschl, C, Tomecek, D, Skoch, A, van Amelsvoort, T, Bakker, G, James, A, Preda, A, Weideman, A, Stein, DJ, Howells, F, Uhlmann, A, Temmingh, H, López-Jaramillo, C, Díaz-Zuluaga, A, Fortea, L, Martinez-Heras, E, Solana, E, Llufriu, S, Jahanshad, N, Thompson, P, Turner, J, van Erp, T, Glahn, D, Pearlson, G, Hong, E, Krug, A, Carr, V, Tooney, P, Cooper, G, Rasser, P, Michie, P, Catts, S, Gur, R, Yang, F, Fan, F, Chen, J, Guo, H, and Tan, S

Abstract

A common limitation of neuroimaging studies is their small sample sizes. To overcome this hurdle, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium combines neuroimaging data from many institutions worldwide. However, this introduces heterogeneity due to different scanning devices and sequences. ENIGMA projects commonly address this heterogeneity with random-effects meta-analysis or mixed-effects mega-analysis. Here we tested whether the batch adjustment method, ComBat, can further reduce site-related heterogeneity and thus increase statistical power. We conducted random-effects meta-analyses, mixed-effects mega-analyses and ComBat mega-analyses to compare cortical thickness, surface area and subcortical volumes between 2897 individuals with a diagnosis of schizophrenia and 3141 healthy controls from 33 sites. Specifically, we compared the imaging data between individuals with schizophrenia and healthy controls, covarying for age and sex. The use of ComBat substantially increased the statistical significance of the findings as compared to random-effects meta-analyses. The findings were more similar when comparing ComBat with mixed-effects mega-analysis, although ComBat still slightly increased the statistical significance. ComBat also showed increased statistical power when we repeated the analyses with fewer sites. Results were nearly identical when we applied the ComBat harmonization separately for cortical thickness, cortical surface area and subcortical volumes. Therefore, we recommend applying the ComBat function to attenuate potential effects of site in ENIGMA projects and other multi-site structural imaging work. We provide easy-to-use functions in R that work even if imaging data are partially missing in some brain regions, and they can be trained with one data set and then applied to another (a requirement for some analyses such as machine learning).

Published
2020

50. Increased power by harmonizing structural MRI site differences with the ComBat batch method in ENIGMA

Author

Radua, J, Vieta, E, Shinohara, R, Kochunov, P, Quide, Y, Green, MJ, Weickert, CS, Weickert, T, Bruggemann, J, Kircher, T, Nenadic, I, Cairns, MJ, Seal, M, Schall, U, Henskens, F, Fullerton, JM, Mowry, B, Pantelis, C, Lenroot, R, Cropley, V, Loughland, C, Scott, R, Wolf, D, Satterthwaite, TD, Tan, Y, Sim, K, Piras, F, Spalletta, G, Banaj, N, Pomarol-Clotet, E, Solanes, A, Albajes-Eizagirre, A, Canales-Rodriguez, EJ, Sarro, S, Di Giorgio, A, Bertolino, A, Staeblein, M, Oertel, V, Knoechel, C, Borgwardt, S, du Plessis, S, Yun, J-Y, Kwon, JS, Dannlowski, U, Hahn, T, Grotegerd, D, Alloza, C, Arango, C, Janssen, J, Diaz-Caneja, C, Jiang, W, Calhoun, V, Ehrlich, S, Yang, K, Cascella, NG, Takayanagi, Y, Sawa, A, Tomyshev, A, Lebedeva, I, Kaleda, V, Kirschner, M, Hoschl, C, Tomecek, D, Skoch, A, van Amelsvoort, T, Bakker, G, James, A, Preda, A, Weideman, A, Stein, DJ, Howells, F, Uhlmann, A, Temmingh, H, Lopez-Jaramillo, C, Diaz-Zuluaga, A, Fortea, L, Martinez-Heras, E, Solana, E, Llufriu, S, Jahanshad, N, Thompson, P, Turner, J, van Erp, T, Radua, J, Vieta, E, Shinohara, R, Kochunov, P, Quide, Y, Green, MJ, Weickert, CS, Weickert, T, Bruggemann, J, Kircher, T, Nenadic, I, Cairns, MJ, Seal, M, Schall, U, Henskens, F, Fullerton, JM, Mowry, B, Pantelis, C, Lenroot, R, Cropley, V, Loughland, C, Scott, R, Wolf, D, Satterthwaite, TD, Tan, Y, Sim, K, Piras, F, Spalletta, G, Banaj, N, Pomarol-Clotet, E, Solanes, A, Albajes-Eizagirre, A, Canales-Rodriguez, EJ, Sarro, S, Di Giorgio, A, Bertolino, A, Staeblein, M, Oertel, V, Knoechel, C, Borgwardt, S, du Plessis, S, Yun, J-Y, Kwon, JS, Dannlowski, U, Hahn, T, Grotegerd, D, Alloza, C, Arango, C, Janssen, J, Diaz-Caneja, C, Jiang, W, Calhoun, V, Ehrlich, S, Yang, K, Cascella, NG, Takayanagi, Y, Sawa, A, Tomyshev, A, Lebedeva, I, Kaleda, V, Kirschner, M, Hoschl, C, Tomecek, D, Skoch, A, van Amelsvoort, T, Bakker, G, James, A, Preda, A, Weideman, A, Stein, DJ, Howells, F, Uhlmann, A, Temmingh, H, Lopez-Jaramillo, C, Diaz-Zuluaga, A, Fortea, L, Martinez-Heras, E, Solana, E, Llufriu, S, Jahanshad, N, Thompson, P, Turner, J, and van Erp, T

Abstract

A common limitation of neuroimaging studies is their small sample sizes. To overcome this hurdle, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium combines neuroimaging data from many institutions worldwide. However, this introduces heterogeneity due to different scanning devices and sequences. ENIGMA projects commonly address this heterogeneity with random-effects meta-analysis or mixed-effects mega-analysis. Here we tested whether the batch adjustment method, ComBat, can further reduce site-related heterogeneity and thus increase statistical power. We conducted random-effects meta-analyses, mixed-effects mega-analyses and ComBat mega-analyses to compare cortical thickness, surface area and subcortical volumes between 2897 individuals with a diagnosis of schizophrenia and 3141 healthy controls from 33 sites. Specifically, we compared the imaging data between individuals with schizophrenia and healthy controls, covarying for age and sex. The use of ComBat substantially increased the statistical significance of the findings as compared to random-effects meta-analyses. The findings were more similar when comparing ComBat with mixed-effects mega-analysis, although ComBat still slightly increased the statistical significance. ComBat also showed increased statistical power when we repeated the analyses with fewer sites. Results were nearly identical when we applied the ComBat harmonization separately for cortical thickness, cortical surface area and subcortical volumes. Therefore, we recommend applying the ComBat function to attenuate potential effects of site in ENIGMA projects and other multi-site structural imaging work. We provide easy-to-use functions in R that work even if imaging data are partially missing in some brain regions, and they can be trained with one data set and then applied to another (a requirement for some analyses such as machine learning).

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results